Sexual Health

Interviews with a small sample of veterans seeking disability compensation for military sexual trauma (MST) reveal the US Department of Veterans Affairs (VA) claims process may retraumatize victims by invalidating their experiences and forcing them to relive their assaults, according to a new report.

For some victims, “retraumatization and invalidation contributed to perceptions of VA-enacted institutional betrayal, which impacted their trust in and likelihood of using VA health care,” report Aliya R. Webermann, PhD, of VA Connecticut Healthcare System and Yale School of Medicine, et al in the Journal of Trauma & Dissociation.

One participant recalled that having to write about her trauma “was a big trigger. It was hard. When I was typing it, in the back of my mind, that’s all I could remember. It’s like going through this whole thing all over again.” Another described writing her statement as “brutal.”

Clinical psychologist Anne P. DePrince, PhD, a professor at the University of Denver not involved in the research, said in an interview with Federal Practitioner that the findings “add to a growing number of studies showing that institutional policies can be more than just red tape.

“Policies and procedures, and how those are implemented by staff, can have real consequences for survivors of intimate abuse, adding to the psychological burden they bear.”

The Burden of Military Sexual Trauma

According to a 2016 meta-analysis, 15.7% of US service members and veterans have experienced MST when measured as combined sexual assault and harassment. Viewed separately, assault was reported by 13.9%, including 23.6% of women and 1.9% of men, while harassment was reported by 31.2%, including 52.5% of women and 8.9% of men. The VA defines MST as “sexual assault or threatening sexual harassment experienced during military service.” MST has been linked to posttraumatic stress disorder (PTSD), substance misuse, suicidality, and other adverse outcomes, the new study notes.

Veterans are eligible for service-connected disability compensation for any condition, such as PTSD precipitated by MST, the study authors write, but patients must provide evidence of the trauma and show that the MST caused their disability.

A 2024 analysis found that MST-related PTSD claims for disability were more likely to be denied than combat-related PTSD claims (27.6% vs 18.2%, respectively).

‘I Had to Relive All of That Again’

The researchers recruited 15 victims of MST for interviews in 2024 (73% women, 60% White, 60% Army, mean age 52.6 years). Most served prior to 9/11 and lived in a single state.

In the conversations, which addressed the MST-related claims process, participants described being forced to repeat their stories. “When it was time for me to sit down and write, I had to relive all of that again. It was kind of rough,” one participant said.

Four veterans said being asked to recall their traumas was especially difficult when they were already doing so as part of treatment: “Through therapy, I gotta keep telling the same thing over and over, and it gets old . . . isn’t once enough?” said one veteran, while a male veteran said the experience was “like a knife going into your gut all the time.”

Victims Told They Don’t Fit the Mold

Veterans also described stress during the process.

“It would make me shut down,” said one participant about trying to appeal an initial 10% disability rating. “I used to drink a lot. It took a toll not just on me, but on my relationship.”

Two of the 15 veterans were denied disability, and they described reading their files as traumatic.

“When I read what they put, sometimes I feel as if I’m being assaulted all over again,” one said.

Additionally, some veterans “described being confronted when their lives did not follow a simple pattern of behavior before and after their MST,” the authors write.

One female veteran said: “They were like, ‘But you continued to perform so well and do well in class and still be able to be a military rock star.’ People deal with trauma in different ways. I don’t have to do a 180 and s— the bed to show this is impacting me.”

In other comments, veterans spoke about racial divides—the 2024 analysis found Black veterans were more likely to be denied MST-related disability claims than White veterans—“the living hell” of denied claims, and perceptions of the VA as “an institutional adversary that was distrustful and untrustworthy.”

DePrince said the study highlights the importance of preparing trauma survivors for what they will experience in the claims process.

“My team has learned from survivors across multiple studies just how important clear and accurate information is when trying to navigate legal, health, and social service systems,” she said. “Unfortunately, many survivors find it hard to get clear and accurate information about these processes, which adds to the stress of trying to access much-needed care and resources after trauma.”

Clinical psychologist Sheela Raja, PhD, an associate professor at the University of Illinois Chicago who studies how trauma affects survivors, agreed with DePrince in an interview with Federal Practitioner.

“When survivors know what’s coming, they can prepare, and that alone can make a huge difference,” said Raja, who was familiar with the study findings.

Raja, who has written books about trauma and PTSD, called research such as this “essential.” These reports bring “survivors’ voices forward and help us understand not just their experiences, but the symptoms and stress that can come from navigating systems that weren’t designed with trauma in mind.”

The VA funded the study. The authors have no disclosures. DePrince is associate editor of the Journal of Trauma and Dissociation, where the study appeared, but she was not involved in the review of the paper. Raja has no disclosures.

Interviews with a small sample of veterans seeking disability compensation for military sexual trauma (MST) reveal the US Department of Veterans Affairs (VA) claims process may retraumatize victims by invalidating their experiences and forcing them to relive their assaults, according to a new report.

For some victims, “retraumatization and invalidation contributed to perceptions of VA-enacted institutional betrayal, which impacted their trust in and likelihood of using VA health care,” report Aliya R. Webermann, PhD, of VA Connecticut Healthcare System and Yale School of Medicine, et al in the Journal of Trauma & Dissociation.

One participant recalled that having to write about her trauma “was a big trigger. It was hard. When I was typing it, in the back of my mind, that’s all I could remember. It’s like going through this whole thing all over again.” Another described writing her statement as “brutal.”

Clinical psychologist Anne P. DePrince, PhD, a professor at the University of Denver not involved in the research, said in an interview with Federal Practitioner that the findings “add to a growing number of studies showing that institutional policies can be more than just red tape.

“Policies and procedures, and how those are implemented by staff, can have real consequences for survivors of intimate abuse, adding to the psychological burden they bear.”

The Burden of Military Sexual Trauma

According to a 2016 meta-analysis, 15.7% of US service members and veterans have experienced MST when measured as combined sexual assault and harassment. Viewed separately, assault was reported by 13.9%, including 23.6% of women and 1.9% of men, while harassment was reported by 31.2%, including 52.5% of women and 8.9% of men. The VA defines MST as “sexual assault or threatening sexual harassment experienced during military service.” MST has been linked to posttraumatic stress disorder (PTSD), substance misuse, suicidality, and other adverse outcomes, the new study notes.

Veterans are eligible for service-connected disability compensation for any condition, such as PTSD precipitated by MST, the study authors write, but patients must provide evidence of the trauma and show that the MST caused their disability.

A 2024 analysis found that MST-related PTSD claims for disability were more likely to be denied than combat-related PTSD claims (27.6% vs 18.2%, respectively).

‘I Had to Relive All of That Again’

The researchers recruited 15 victims of MST for interviews in 2024 (73% women, 60% White, 60% Army, mean age 52.6 years). Most served prior to 9/11 and lived in a single state.

In the conversations, which addressed the MST-related claims process, participants described being forced to repeat their stories. “When it was time for me to sit down and write, I had to relive all of that again. It was kind of rough,” one participant said.

Four veterans said being asked to recall their traumas was especially difficult when they were already doing so as part of treatment: “Through therapy, I gotta keep telling the same thing over and over, and it gets old . . . isn’t once enough?” said one veteran, while a male veteran said the experience was “like a knife going into your gut all the time.”

Victims Told They Don’t Fit the Mold

Veterans also described stress during the process.

“It would make me shut down,” said one participant about trying to appeal an initial 10% disability rating. “I used to drink a lot. It took a toll not just on me, but on my relationship.”

Two of the 15 veterans were denied disability, and they described reading their files as traumatic.

“When I read what they put, sometimes I feel as if I’m being assaulted all over again,” one said.

Additionally, some veterans “described being confronted when their lives did not follow a simple pattern of behavior before and after their MST,” the authors write.

One female veteran said: “They were like, ‘But you continued to perform so well and do well in class and still be able to be a military rock star.’ People deal with trauma in different ways. I don’t have to do a 180 and s— the bed to show this is impacting me.”

In other comments, veterans spoke about racial divides—the 2024 analysis found Black veterans were more likely to be denied MST-related disability claims than White veterans—“the living hell” of denied claims, and perceptions of the VA as “an institutional adversary that was distrustful and untrustworthy.”

DePrince said the study highlights the importance of preparing trauma survivors for what they will experience in the claims process.

“My team has learned from survivors across multiple studies just how important clear and accurate information is when trying to navigate legal, health, and social service systems,” she said. “Unfortunately, many survivors find it hard to get clear and accurate information about these processes, which adds to the stress of trying to access much-needed care and resources after trauma.”

Clinical psychologist Sheela Raja, PhD, an associate professor at the University of Illinois Chicago who studies how trauma affects survivors, agreed with DePrince in an interview with Federal Practitioner.

“When survivors know what’s coming, they can prepare, and that alone can make a huge difference,” said Raja, who was familiar with the study findings.

Raja, who has written books about trauma and PTSD, called research such as this “essential.” These reports bring “survivors’ voices forward and help us understand not just their experiences, but the symptoms and stress that can come from navigating systems that weren’t designed with trauma in mind.”

The VA funded the study. The authors have no disclosures. DePrince is associate editor of the Journal of Trauma and Dissociation, where the study appeared, but she was not involved in the review of the paper. Raja has no disclosures.

Interviews with a small sample of veterans seeking disability compensation for military sexual trauma (MST) reveal the US Department of Veterans Affairs (VA) claims process may retraumatize victims by invalidating their experiences and forcing them to relive their assaults, according to a new report.

For some victims, “retraumatization and invalidation contributed to perceptions of VA-enacted institutional betrayal, which impacted their trust in and likelihood of using VA health care,” report Aliya R. Webermann, PhD, of VA Connecticut Healthcare System and Yale School of Medicine, et al in the Journal of Trauma & Dissociation.

One participant recalled that having to write about her trauma “was a big trigger. It was hard. When I was typing it, in the back of my mind, that’s all I could remember. It’s like going through this whole thing all over again.” Another described writing her statement as “brutal.”

Clinical psychologist Anne P. DePrince, PhD, a professor at the University of Denver not involved in the research, said in an interview with Federal Practitioner that the findings “add to a growing number of studies showing that institutional policies can be more than just red tape.

“Policies and procedures, and how those are implemented by staff, can have real consequences for survivors of intimate abuse, adding to the psychological burden they bear.”

The Burden of Military Sexual Trauma

According to a 2016 meta-analysis, 15.7% of US service members and veterans have experienced MST when measured as combined sexual assault and harassment. Viewed separately, assault was reported by 13.9%, including 23.6% of women and 1.9% of men, while harassment was reported by 31.2%, including 52.5% of women and 8.9% of men. The VA defines MST as “sexual assault or threatening sexual harassment experienced during military service.” MST has been linked to posttraumatic stress disorder (PTSD), substance misuse, suicidality, and other adverse outcomes, the new study notes.

Veterans are eligible for service-connected disability compensation for any condition, such as PTSD precipitated by MST, the study authors write, but patients must provide evidence of the trauma and show that the MST caused their disability.

A 2024 analysis found that MST-related PTSD claims for disability were more likely to be denied than combat-related PTSD claims (27.6% vs 18.2%, respectively).

‘I Had to Relive All of That Again’

The researchers recruited 15 victims of MST for interviews in 2024 (73% women, 60% White, 60% Army, mean age 52.6 years). Most served prior to 9/11 and lived in a single state.

In the conversations, which addressed the MST-related claims process, participants described being forced to repeat their stories. “When it was time for me to sit down and write, I had to relive all of that again. It was kind of rough,” one participant said.

Four veterans said being asked to recall their traumas was especially difficult when they were already doing so as part of treatment: “Through therapy, I gotta keep telling the same thing over and over, and it gets old . . . isn’t once enough?” said one veteran, while a male veteran said the experience was “like a knife going into your gut all the time.”

Victims Told They Don’t Fit the Mold

Veterans also described stress during the process.

“It would make me shut down,” said one participant about trying to appeal an initial 10% disability rating. “I used to drink a lot. It took a toll not just on me, but on my relationship.”

Two of the 15 veterans were denied disability, and they described reading their files as traumatic.

“When I read what they put, sometimes I feel as if I’m being assaulted all over again,” one said.

Additionally, some veterans “described being confronted when their lives did not follow a simple pattern of behavior before and after their MST,” the authors write.

One female veteran said: “They were like, ‘But you continued to perform so well and do well in class and still be able to be a military rock star.’ People deal with trauma in different ways. I don’t have to do a 180 and s— the bed to show this is impacting me.”

In other comments, veterans spoke about racial divides—the 2024 analysis found Black veterans were more likely to be denied MST-related disability claims than White veterans—“the living hell” of denied claims, and perceptions of the VA as “an institutional adversary that was distrustful and untrustworthy.”

DePrince said the study highlights the importance of preparing trauma survivors for what they will experience in the claims process.

“My team has learned from survivors across multiple studies just how important clear and accurate information is when trying to navigate legal, health, and social service systems,” she said. “Unfortunately, many survivors find it hard to get clear and accurate information about these processes, which adds to the stress of trying to access much-needed care and resources after trauma.”

Clinical psychologist Sheela Raja, PhD, an associate professor at the University of Illinois Chicago who studies how trauma affects survivors, agreed with DePrince in an interview with Federal Practitioner.

“When survivors know what’s coming, they can prepare, and that alone can make a huge difference,” said Raja, who was familiar with the study findings.

Raja, who has written books about trauma and PTSD, called research such as this “essential.” These reports bring “survivors’ voices forward and help us understand not just their experiences, but the symptoms and stress that can come from navigating systems that weren’t designed with trauma in mind.”

The VA funded the study. The authors have no disclosures. DePrince is associate editor of the Journal of Trauma and Dissociation, where the study appeared, but she was not involved in the review of the paper. Raja has no disclosures.

The number of sexual assaults in the US military dropped for the first time in a decade, according an annual report from the Pentagon, while benefits claims for assault survivors are on the rise. 

     Records show that 29,000 active-duty members reported being sexually assaulted in 2023, or 7000 fewer than in 2021. A confidential survey also found the number of service members who experienced some type of unwanted sexual contact dropped nearly 20%, leaving the Pentagon “cautiously optimistic“ its investments in preventing sexual assault and building a healthy climate are having an impact.

     Despite these investments, issues persist. An Army anesthesiologist recently pleaded guilty to 41 charges of sexual misconduct involving 21 victims at Madigan Army Medical Center at Joint Base Lewis-McChord in Washington. The alleged incidents occurred between 2019 and 2022 and involved the doctor unnecessarily focusing on the genital area of patients during what he described as routine examinations. Maj. Michael Stockin faces nearly 14 years in prison, should the judge accept the plea agreement Stockin and his attorneys made with government prosecutors.

     Additionally, a report from the Watson Institute of International and Public Affairs at Brown University indicated that 24% of active-duty women and 1.9% of active-duty men experienced sexual assault from 2001 to 2021.During post-9/11 wars, “the prioritization of force readiness above all else allowed the problem of sexual assault to fester, papering over internal violence and gender inequalities within military institutions,” the report said. There was also a slight uptick in reports of military sexual assaults in 2020, when troops were largely on lockdown as a result of the COVID-19 pandemic.

     Efforts to address sexual assault in the military have increased in the past 10 years to the tune of 10 Department of Defense Inspector General engagements, 60 Government Accountability Office recommendations, > 200 government panel and task force recommendations, > 150 Congressional provisions, and > 50 Secretary of Defense initiatives. Additionally, the 2022 National Defense Authorization gave authority in sexual assault cases to independent prosecutors rather than commanders. Other reforms have included incorporating trauma-informed practices in the claims process.

     Meanwhile, the US Department of Veterans Affairs (VA) has also been attempting to convince more sexual assault survivors to file claims for benefits. Assistant Deputy Under Secretary for Field Operations Kenesha Britton said in December that the VA has held 3500 events in the past 14 months focused on benefits for victims of military sexual assault and harassment. It appears to be working, as the VA received 57,400 claims for military sexual trauma in fiscal year 2024 (an 18% increase from 2023), and approved > 63% of them, compared to 40% more than a decade ago. Prior to Oct. 1, VA staffers processed > 11,000 cases in a single day twice. Since that date, they have processed that amount on 9 separate occasions.

     “We recognize the remarkable courage it takes for survivors of military sexual trauma to seek the benefits and support they’ve earned,” Britton said. “Our mission is driven by a commitment to ensure survivors are met with care, dignity and sensitivity throughout the claims process.”

     The increase in trust is a byproduct of the outreach campaigns, VA Under Secretary for Benefits Josh Jacobs said: “[M]ore veterans are coming in to apply for benefits and I think that has to do with building trust because we are actively trying to reach veterans telling them we want to connect them with their earned benefits.”

The number of sexual assaults in the US military dropped for the first time in a decade, according an annual report from the Pentagon, while benefits claims for assault survivors are on the rise. 

     Records show that 29,000 active-duty members reported being sexually assaulted in 2023, or 7000 fewer than in 2021. A confidential survey also found the number of service members who experienced some type of unwanted sexual contact dropped nearly 20%, leaving the Pentagon “cautiously optimistic“ its investments in preventing sexual assault and building a healthy climate are having an impact.

     Despite these investments, issues persist. An Army anesthesiologist recently pleaded guilty to 41 charges of sexual misconduct involving 21 victims at Madigan Army Medical Center at Joint Base Lewis-McChord in Washington. The alleged incidents occurred between 2019 and 2022 and involved the doctor unnecessarily focusing on the genital area of patients during what he described as routine examinations. Maj. Michael Stockin faces nearly 14 years in prison, should the judge accept the plea agreement Stockin and his attorneys made with government prosecutors.

     Additionally, a report from the Watson Institute of International and Public Affairs at Brown University indicated that 24% of active-duty women and 1.9% of active-duty men experienced sexual assault from 2001 to 2021.During post-9/11 wars, “the prioritization of force readiness above all else allowed the problem of sexual assault to fester, papering over internal violence and gender inequalities within military institutions,” the report said. There was also a slight uptick in reports of military sexual assaults in 2020, when troops were largely on lockdown as a result of the COVID-19 pandemic.

     Efforts to address sexual assault in the military have increased in the past 10 years to the tune of 10 Department of Defense Inspector General engagements, 60 Government Accountability Office recommendations, > 200 government panel and task force recommendations, > 150 Congressional provisions, and > 50 Secretary of Defense initiatives. Additionally, the 2022 National Defense Authorization gave authority in sexual assault cases to independent prosecutors rather than commanders. Other reforms have included incorporating trauma-informed practices in the claims process.

     Meanwhile, the US Department of Veterans Affairs (VA) has also been attempting to convince more sexual assault survivors to file claims for benefits. Assistant Deputy Under Secretary for Field Operations Kenesha Britton said in December that the VA has held 3500 events in the past 14 months focused on benefits for victims of military sexual assault and harassment. It appears to be working, as the VA received 57,400 claims for military sexual trauma in fiscal year 2024 (an 18% increase from 2023), and approved > 63% of them, compared to 40% more than a decade ago. Prior to Oct. 1, VA staffers processed > 11,000 cases in a single day twice. Since that date, they have processed that amount on 9 separate occasions.

     “We recognize the remarkable courage it takes for survivors of military sexual trauma to seek the benefits and support they’ve earned,” Britton said. “Our mission is driven by a commitment to ensure survivors are met with care, dignity and sensitivity throughout the claims process.”

     The increase in trust is a byproduct of the outreach campaigns, VA Under Secretary for Benefits Josh Jacobs said: “[M]ore veterans are coming in to apply for benefits and I think that has to do with building trust because we are actively trying to reach veterans telling them we want to connect them with their earned benefits.”

The number of sexual assaults in the US military dropped for the first time in a decade, according an annual report from the Pentagon, while benefits claims for assault survivors are on the rise. 

     Records show that 29,000 active-duty members reported being sexually assaulted in 2023, or 7000 fewer than in 2021. A confidential survey also found the number of service members who experienced some type of unwanted sexual contact dropped nearly 20%, leaving the Pentagon “cautiously optimistic“ its investments in preventing sexual assault and building a healthy climate are having an impact.

     Despite these investments, issues persist. An Army anesthesiologist recently pleaded guilty to 41 charges of sexual misconduct involving 21 victims at Madigan Army Medical Center at Joint Base Lewis-McChord in Washington. The alleged incidents occurred between 2019 and 2022 and involved the doctor unnecessarily focusing on the genital area of patients during what he described as routine examinations. Maj. Michael Stockin faces nearly 14 years in prison, should the judge accept the plea agreement Stockin and his attorneys made with government prosecutors.

     Additionally, a report from the Watson Institute of International and Public Affairs at Brown University indicated that 24% of active-duty women and 1.9% of active-duty men experienced sexual assault from 2001 to 2021.During post-9/11 wars, “the prioritization of force readiness above all else allowed the problem of sexual assault to fester, papering over internal violence and gender inequalities within military institutions,” the report said. There was also a slight uptick in reports of military sexual assaults in 2020, when troops were largely on lockdown as a result of the COVID-19 pandemic.

     Efforts to address sexual assault in the military have increased in the past 10 years to the tune of 10 Department of Defense Inspector General engagements, 60 Government Accountability Office recommendations, > 200 government panel and task force recommendations, > 150 Congressional provisions, and > 50 Secretary of Defense initiatives. Additionally, the 2022 National Defense Authorization gave authority in sexual assault cases to independent prosecutors rather than commanders. Other reforms have included incorporating trauma-informed practices in the claims process.

     Meanwhile, the US Department of Veterans Affairs (VA) has also been attempting to convince more sexual assault survivors to file claims for benefits. Assistant Deputy Under Secretary for Field Operations Kenesha Britton said in December that the VA has held 3500 events in the past 14 months focused on benefits for victims of military sexual assault and harassment. It appears to be working, as the VA received 57,400 claims for military sexual trauma in fiscal year 2024 (an 18% increase from 2023), and approved > 63% of them, compared to 40% more than a decade ago. Prior to Oct. 1, VA staffers processed > 11,000 cases in a single day twice. Since that date, they have processed that amount on 9 separate occasions.

     “We recognize the remarkable courage it takes for survivors of military sexual trauma to seek the benefits and support they’ve earned,” Britton said. “Our mission is driven by a commitment to ensure survivors are met with care, dignity and sensitivity throughout the claims process.”

     The increase in trust is a byproduct of the outreach campaigns, VA Under Secretary for Benefits Josh Jacobs said: “[M]ore veterans are coming in to apply for benefits and I think that has to do with building trust because we are actively trying to reach veterans telling them we want to connect them with their earned benefits.”

TOPLINE:

Oral doxycycline (200 mg twice daily for 28 days) appears to be as effective as intravenous (IV) penicillin for the treatment of ocular syphilis for some patients with the condition.

METHODOLOGY:

• Researchers conducted a retrospective cohort study of ocular syphilis cases diagnosed from 2017 to 2023 in Los Angeles, analyzing 32 patients with a median age of 46 years (78% men).
• Patients treated before January 2022 received IV doxycycline, while those treated after that date were given the option to receive an oral form of the drug.
• A total of 16 patients received oral doxycycline (seven patients received only oral doxycycline; nine received a short course of parenteral penicillin followed by a full course of oral doxycycline); another 16 patients received a full course of IV penicillin.
• The analysis measured visual acuity (VA), ocular inflammation, and rapid plasma reagin (RPR).

TAKEAWAY:

• The doxycycline group had better median VA at both the initial presentation and the final follow-up than the penicillin group (VA, 0.44, 0.18; P = .04; VA, 1.0, 0.40; P = .03, respectively).
• Resolution of ocular inflammation showed no significant differences between the doxycycline and IV penicillin groups (P = .62 for both).
• All patients who had follow-up at 9 months demonstrated a fourfold decrease in RPR titers (four people in the oral doxycycline group and seven people in the IV penicillin group).

IN PRACTICE:

“We found that oral doxycycline for the treatment of ocular syphilis may be safe and effective in a selected subset of patients who completed an extended oral antibiotic regimen,” the study authors wrote. “Other studies have also demonstrated similar efficacy of oral therapy when compared with IV therapy. A fourfold decrease in RPR titers was considered an adequate serologic treatment response and corresponds with resolution of syphilis disease activity. This was observed in all patients with more than 9 months of follow-up. Long-term monitoring is recommended for those treated with doxycycline to ensure clinical and serologic response.”

SOURCE:

The study was led by Brian C. Toy, MD, of the Roski Eye Institute at the Keck School of Medicine at the University of Southern California in Los Angeles. It was published online in JAMA Network Open.

LIMITATIONS:

The study was retrospective in nature, used heterogeneous treatment methods, and lacked longitudinal RPR titers.

DISCLOSURES:

Toy served on physician advisory boards for Alimera, EyePoint, Bausch and Lomb, and Regeneron. No other disclosures were reported.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

A version of this article first appeared on Medscape.com.

TOPLINE:

Oral doxycycline (200 mg twice daily for 28 days) appears to be as effective as intravenous (IV) penicillin for the treatment of ocular syphilis for some patients with the condition.

METHODOLOGY:

• Researchers conducted a retrospective cohort study of ocular syphilis cases diagnosed from 2017 to 2023 in Los Angeles, analyzing 32 patients with a median age of 46 years (78% men).
• Patients treated before January 2022 received IV doxycycline, while those treated after that date were given the option to receive an oral form of the drug.
• A total of 16 patients received oral doxycycline (seven patients received only oral doxycycline; nine received a short course of parenteral penicillin followed by a full course of oral doxycycline); another 16 patients received a full course of IV penicillin.
• The analysis measured visual acuity (VA), ocular inflammation, and rapid plasma reagin (RPR).

TAKEAWAY:

• The doxycycline group had better median VA at both the initial presentation and the final follow-up than the penicillin group (VA, 0.44, 0.18; P = .04; VA, 1.0, 0.40; P = .03, respectively).
• Resolution of ocular inflammation showed no significant differences between the doxycycline and IV penicillin groups (P = .62 for both).
• All patients who had follow-up at 9 months demonstrated a fourfold decrease in RPR titers (four people in the oral doxycycline group and seven people in the IV penicillin group).

IN PRACTICE:

“We found that oral doxycycline for the treatment of ocular syphilis may be safe and effective in a selected subset of patients who completed an extended oral antibiotic regimen,” the study authors wrote. “Other studies have also demonstrated similar efficacy of oral therapy when compared with IV therapy. A fourfold decrease in RPR titers was considered an adequate serologic treatment response and corresponds with resolution of syphilis disease activity. This was observed in all patients with more than 9 months of follow-up. Long-term monitoring is recommended for those treated with doxycycline to ensure clinical and serologic response.”

SOURCE:

The study was led by Brian C. Toy, MD, of the Roski Eye Institute at the Keck School of Medicine at the University of Southern California in Los Angeles. It was published online in JAMA Network Open.

LIMITATIONS:

The study was retrospective in nature, used heterogeneous treatment methods, and lacked longitudinal RPR titers.

DISCLOSURES:

Toy served on physician advisory boards for Alimera, EyePoint, Bausch and Lomb, and Regeneron. No other disclosures were reported.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

A version of this article first appeared on Medscape.com.

TOPLINE:

Oral doxycycline (200 mg twice daily for 28 days) appears to be as effective as intravenous (IV) penicillin for the treatment of ocular syphilis for some patients with the condition.

METHODOLOGY:

• Researchers conducted a retrospective cohort study of ocular syphilis cases diagnosed from 2017 to 2023 in Los Angeles, analyzing 32 patients with a median age of 46 years (78% men).
• Patients treated before January 2022 received IV doxycycline, while those treated after that date were given the option to receive an oral form of the drug.
• A total of 16 patients received oral doxycycline (seven patients received only oral doxycycline; nine received a short course of parenteral penicillin followed by a full course of oral doxycycline); another 16 patients received a full course of IV penicillin.
• The analysis measured visual acuity (VA), ocular inflammation, and rapid plasma reagin (RPR).

TAKEAWAY:

• The doxycycline group had better median VA at both the initial presentation and the final follow-up than the penicillin group (VA, 0.44, 0.18; P = .04; VA, 1.0, 0.40; P = .03, respectively).
• Resolution of ocular inflammation showed no significant differences between the doxycycline and IV penicillin groups (P = .62 for both).
• All patients who had follow-up at 9 months demonstrated a fourfold decrease in RPR titers (four people in the oral doxycycline group and seven people in the IV penicillin group).

IN PRACTICE:

“We found that oral doxycycline for the treatment of ocular syphilis may be safe and effective in a selected subset of patients who completed an extended oral antibiotic regimen,” the study authors wrote. “Other studies have also demonstrated similar efficacy of oral therapy when compared with IV therapy. A fourfold decrease in RPR titers was considered an adequate serologic treatment response and corresponds with resolution of syphilis disease activity. This was observed in all patients with more than 9 months of follow-up. Long-term monitoring is recommended for those treated with doxycycline to ensure clinical and serologic response.”

SOURCE:

The study was led by Brian C. Toy, MD, of the Roski Eye Institute at the Keck School of Medicine at the University of Southern California in Los Angeles. It was published online in JAMA Network Open.

LIMITATIONS:

The study was retrospective in nature, used heterogeneous treatment methods, and lacked longitudinal RPR titers.

DISCLOSURES:

Toy served on physician advisory boards for Alimera, EyePoint, Bausch and Lomb, and Regeneron. No other disclosures were reported.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

A version of this article first appeared on Medscape.com.

Ringworm (also known as tinea, jock itch, or athlete’s foot) is a common infection caused by dermatophyte fungi, known to affect skin, hair, or nails. It causes skin infections that are typically mild and are often treated with topical antifungals.

However, in recent years, newly emerging dermatophyte strains have been causing more severe and harder-to-treat ringworm. Notably, one emerging strain, Trichophyton mentagrophytes genotype VII(TMVII), is associated with sexual contact. In recent years, TMVII infections linked to sexual contact have been reported among men who have sex with men in Europe and in travelers returning from Southeast Asia. The first US case of TMVII was reported in June 2024, after which public health authorities were alerted to additional cases; all were associated with recent sexual contact. Other dermatophyte species have also been reported to cause ringworm transmitted through sexual contact. 

Here are some key points to know about sexually transmitted ringworm. 

Tell me more about sexually transmitted ringworm: What is causing it?

Skin-to-skin contact is a common mode of ringworm transmission. In recent years, transmission of ringworm via intimate or sexual contact has been increasingly recognized. However, clinicians may not immediately consider ringworm when evaluating genital, facial, or perianal lesions. Infections with sexually transmitted TMVII commonly cause lesions on anatomical sites that may be exposed during intimate or sexual contact, such as the face, genitals, and perianal region. Sexual transmission of TMVII has been reported in Europe, predominantly among men who have sex with men, for several years. Other dermatophyte strains have been reported in association with sexual contact, including the emerging strain Trichophyton indotineae. However, sexual transmission is not the main mode of transmission for T indotineae and other dermatophyte strains. 

When should clinicians suspect a potential case of sexually transmitted ringworm?

Providers should consider sexually transmitted ringworm when seeing ringworm in locations associated with intimate contact (for example, a rash on or around the genitals, perianal area, or mouth). 

The typical appearance of ringworm is a raised, ring-like, erythematous rash with a scaly border that grows over time. The rash may appear pink, brown, or gray on different types of skin. Patients may note itching and flaking of the rash. In areas with hair such as the beard area, ringworm can present as pustules and be associated with hair loss.

Emerging ringworm infections can present in atypical or more severe ways, including a highly inflammatory (painful, scarring, or otherwise severe) rash, a rash affecting a large area or multiple sites, nodules, and pustules. 

Sexually transmitted ringworm may be considered based on sexual history and recent sexual contact with someone with known TMVII. Recent history of travel to a region with reported sexually transmitted ringworm may increase suspicion of TMVII. In patients with a travel history to South Asia, T indotineae should be considered, especially if the rash does not improve with oral terbinafine. 

How can testing help guide the diagnosis of sexually transmitted ringworm infection?

When evaluating a rash that may represent ringworm, providers should use a confirmatory test such as potassium hydroxide (KOH) preparation when possible. KOH prep can confirm the presence of a fungus that causes ringworm, but it does not identify the species or type of ringworm. Testing such as fungal culture and molecular testing can help identify specific types of ringworm, but these tests are not often performed and may take a long time to yield results.

Routine fungal cultures cannot identify TMVII and T indotineae; these tests may identify the genus Trichophyton, but only advanced molecular testing, which is available at selected US laboratories, can identify TMVII and T indotineae. 

We recommend confirmatory testing because ringworm can easily be misdiagnosed as skin conditions such as psoriasis or eczema. The use of topical steroids can worsen a ringworm infection, so clinicians should be cautious about treating a rash with topical steroids if the etiology is unclear. Treatment should not be delayed if testing is not available. 

Clinicians who suspect a case of TMVII infection or infection with another emerging type of severe or antifungal-resistant ringworm can contact the Centers for Disease Control and Prevention (CDC) at fungaloutbreaks@cdc.gov. More details on how clinicians can pursue testing to identify emerging strains of ringworm can be found on the American Academy of Dermatology (AAD) emerging diseases task force website. 

How should clinicians treat and manage sexually transmitted ringworm? 

If TMVII infection is suspected, providers can consider starting empirical treatment with oral terbinafine. Although data are limited, experience from case series suggests that TMVII may require oral antifungal treatment because it can cause severe skin infections and often does not improve with topical antifungals. Clinicians should advise patients that they may need prolonged treatment courses until the rash resolves, with possible need for treatment courses of 6-8 weeks or longer. 

Any diagnosis of a sexually transmitted infection is an opportunity to engage patients in comprehensive sexual health services. Patients with suspected sexually transmitted ringworm should be evaluated for HIV and other sexually transmitted infections, including syphilis, chlamydia, and gonorrhea; clinicians should discuss and facilitate access to other preventive services, such as HIV pre-exposure prophylaxis if the patient is HIV negative and at risk for HIV. Patients should also notify their partner(s) about the diagnosis. 

Is sexually transmitted ringworm a public health concern? 

It is important to know that very few cases of TMVII have been reported in the United States thus far. CDC continues to monitor emerging dermatophyte strains because these types of ringworm can cause more severe or difficult-to-treat infections. Clinicians should be aware of the potential severity of sexually transmitted ringworm infections and of how diagnosis and treatment of these infections may differ from typical management of ringworm.

So far, TMVII, the dermatophyte strain most associated with spread through sexual contact, has not been documented to have antifungal resistance. More rarely, sexually transmitted ringworm may be caused by other emerging dermatophyte strains that are antifungal resistant, such as T indotineae. Itraconazole is the recommended first-line treatment for T indotineae infections. 

How can clinicians counsel patients with sexually transmitted ringworm?

Ringworm can spread with skin-to-skin contact, so patients should avoid such contact with others while they have a rash. They should also avoid sharing personal items (such as razors or towels) and clothing, and launder their clothing, towels, and bedding in a high heat cycle. 

People can reduce their risk of getting all types of ringworm infection by keeping their skin clean and dry, changing their socks and underwear daily, and wearing sandals in public locker rooms and other public spaces. People should avoid skin-to-skin contact with anyone with ringworm or an unexplained rash. Before having sex, people can check in with their partners and be aware of unexplained rashes on their partners’ bodies.

Where can clinicians go to learn more about sexually transmitted and other emerging types of ringworm?

CDC has partnered with the AAD to create set of online resources for clinicians for diagnosing and managing emerging dermatophyte infections. Clinicians who suspect or confirm antimicrobial resistant ringworm infection are also encouraged to submit cases to the AAD’s Emerging Diseases Registry. Clinicians wanting further guidance on how to manage suspected or confirmed ringworm infection with an emerging dermatophyte strain can also contact the CDC at fungaloutbreaks@cdc.gov. Useful information on emerging dermatophyte infections for providers and patients is also available on CDC’s website.

Relevant Reading

Zucker J et al. MMWR Morb Mortal Wkly Rep. 2024;73:985-988.Spivack S et al. Emerg Infect Dis. 2024;30:807-809.Jabet A et al. Emerg Infect Dis. 2023;29:1411-1414.

A version of this article appeared on Medscape.com. 

Dr Anand is Epidemic Intelligence Service Officer, Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. Dr Gold is Medical Officer, Mycotic Diseases Branch, Centers for Disease Control and Prevention. Dr Quilter is Medical Officer, Division of STD Prevention, Centers for Disease Control and Prevention. None reported any relevant conflicts of interest. 

Ringworm (also known as tinea, jock itch, or athlete’s foot) is a common infection caused by dermatophyte fungi, known to affect skin, hair, or nails. It causes skin infections that are typically mild and are often treated with topical antifungals.

However, in recent years, newly emerging dermatophyte strains have been causing more severe and harder-to-treat ringworm. Notably, one emerging strain, Trichophyton mentagrophytes genotype VII(TMVII), is associated with sexual contact. In recent years, TMVII infections linked to sexual contact have been reported among men who have sex with men in Europe and in travelers returning from Southeast Asia. The first US case of TMVII was reported in June 2024, after which public health authorities were alerted to additional cases; all were associated with recent sexual contact. Other dermatophyte species have also been reported to cause ringworm transmitted through sexual contact. 

Here are some key points to know about sexually transmitted ringworm. 

Tell me more about sexually transmitted ringworm: What is causing it?

Skin-to-skin contact is a common mode of ringworm transmission. In recent years, transmission of ringworm via intimate or sexual contact has been increasingly recognized. However, clinicians may not immediately consider ringworm when evaluating genital, facial, or perianal lesions. Infections with sexually transmitted TMVII commonly cause lesions on anatomical sites that may be exposed during intimate or sexual contact, such as the face, genitals, and perianal region. Sexual transmission of TMVII has been reported in Europe, predominantly among men who have sex with men, for several years. Other dermatophyte strains have been reported in association with sexual contact, including the emerging strain Trichophyton indotineae. However, sexual transmission is not the main mode of transmission for T indotineae and other dermatophyte strains. 

When should clinicians suspect a potential case of sexually transmitted ringworm?

Providers should consider sexually transmitted ringworm when seeing ringworm in locations associated with intimate contact (for example, a rash on or around the genitals, perianal area, or mouth). 

The typical appearance of ringworm is a raised, ring-like, erythematous rash with a scaly border that grows over time. The rash may appear pink, brown, or gray on different types of skin. Patients may note itching and flaking of the rash. In areas with hair such as the beard area, ringworm can present as pustules and be associated with hair loss.

Emerging ringworm infections can present in atypical or more severe ways, including a highly inflammatory (painful, scarring, or otherwise severe) rash, a rash affecting a large area or multiple sites, nodules, and pustules. 

Sexually transmitted ringworm may be considered based on sexual history and recent sexual contact with someone with known TMVII. Recent history of travel to a region with reported sexually transmitted ringworm may increase suspicion of TMVII. In patients with a travel history to South Asia, T indotineae should be considered, especially if the rash does not improve with oral terbinafine. 

How can testing help guide the diagnosis of sexually transmitted ringworm infection?

When evaluating a rash that may represent ringworm, providers should use a confirmatory test such as potassium hydroxide (KOH) preparation when possible. KOH prep can confirm the presence of a fungus that causes ringworm, but it does not identify the species or type of ringworm. Testing such as fungal culture and molecular testing can help identify specific types of ringworm, but these tests are not often performed and may take a long time to yield results.

Routine fungal cultures cannot identify TMVII and T indotineae; these tests may identify the genus Trichophyton, but only advanced molecular testing, which is available at selected US laboratories, can identify TMVII and T indotineae. 

We recommend confirmatory testing because ringworm can easily be misdiagnosed as skin conditions such as psoriasis or eczema. The use of topical steroids can worsen a ringworm infection, so clinicians should be cautious about treating a rash with topical steroids if the etiology is unclear. Treatment should not be delayed if testing is not available. 

Clinicians who suspect a case of TMVII infection or infection with another emerging type of severe or antifungal-resistant ringworm can contact the Centers for Disease Control and Prevention (CDC) at fungaloutbreaks@cdc.gov. More details on how clinicians can pursue testing to identify emerging strains of ringworm can be found on the American Academy of Dermatology (AAD) emerging diseases task force website. 

How should clinicians treat and manage sexually transmitted ringworm? 

If TMVII infection is suspected, providers can consider starting empirical treatment with oral terbinafine. Although data are limited, experience from case series suggests that TMVII may require oral antifungal treatment because it can cause severe skin infections and often does not improve with topical antifungals. Clinicians should advise patients that they may need prolonged treatment courses until the rash resolves, with possible need for treatment courses of 6-8 weeks or longer. 

Any diagnosis of a sexually transmitted infection is an opportunity to engage patients in comprehensive sexual health services. Patients with suspected sexually transmitted ringworm should be evaluated for HIV and other sexually transmitted infections, including syphilis, chlamydia, and gonorrhea; clinicians should discuss and facilitate access to other preventive services, such as HIV pre-exposure prophylaxis if the patient is HIV negative and at risk for HIV. Patients should also notify their partner(s) about the diagnosis. 

Is sexually transmitted ringworm a public health concern? 

It is important to know that very few cases of TMVII have been reported in the United States thus far. CDC continues to monitor emerging dermatophyte strains because these types of ringworm can cause more severe or difficult-to-treat infections. Clinicians should be aware of the potential severity of sexually transmitted ringworm infections and of how diagnosis and treatment of these infections may differ from typical management of ringworm.

So far, TMVII, the dermatophyte strain most associated with spread through sexual contact, has not been documented to have antifungal resistance. More rarely, sexually transmitted ringworm may be caused by other emerging dermatophyte strains that are antifungal resistant, such as T indotineae. Itraconazole is the recommended first-line treatment for T indotineae infections. 

How can clinicians counsel patients with sexually transmitted ringworm?

Ringworm can spread with skin-to-skin contact, so patients should avoid such contact with others while they have a rash. They should also avoid sharing personal items (such as razors or towels) and clothing, and launder their clothing, towels, and bedding in a high heat cycle. 

People can reduce their risk of getting all types of ringworm infection by keeping their skin clean and dry, changing their socks and underwear daily, and wearing sandals in public locker rooms and other public spaces. People should avoid skin-to-skin contact with anyone with ringworm or an unexplained rash. Before having sex, people can check in with their partners and be aware of unexplained rashes on their partners’ bodies.

Where can clinicians go to learn more about sexually transmitted and other emerging types of ringworm?

CDC has partnered with the AAD to create set of online resources for clinicians for diagnosing and managing emerging dermatophyte infections. Clinicians who suspect or confirm antimicrobial resistant ringworm infection are also encouraged to submit cases to the AAD’s Emerging Diseases Registry. Clinicians wanting further guidance on how to manage suspected or confirmed ringworm infection with an emerging dermatophyte strain can also contact the CDC at fungaloutbreaks@cdc.gov. Useful information on emerging dermatophyte infections for providers and patients is also available on CDC’s website.

Relevant Reading

Zucker J et al. MMWR Morb Mortal Wkly Rep. 2024;73:985-988.Spivack S et al. Emerg Infect Dis. 2024;30:807-809.Jabet A et al. Emerg Infect Dis. 2023;29:1411-1414.

A version of this article appeared on Medscape.com. 

Dr Anand is Epidemic Intelligence Service Officer, Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. Dr Gold is Medical Officer, Mycotic Diseases Branch, Centers for Disease Control and Prevention. Dr Quilter is Medical Officer, Division of STD Prevention, Centers for Disease Control and Prevention. None reported any relevant conflicts of interest. 

Ringworm (also known as tinea, jock itch, or athlete’s foot) is a common infection caused by dermatophyte fungi, known to affect skin, hair, or nails. It causes skin infections that are typically mild and are often treated with topical antifungals.

However, in recent years, newly emerging dermatophyte strains have been causing more severe and harder-to-treat ringworm. Notably, one emerging strain, Trichophyton mentagrophytes genotype VII(TMVII), is associated with sexual contact. In recent years, TMVII infections linked to sexual contact have been reported among men who have sex with men in Europe and in travelers returning from Southeast Asia. The first US case of TMVII was reported in June 2024, after which public health authorities were alerted to additional cases; all were associated with recent sexual contact. Other dermatophyte species have also been reported to cause ringworm transmitted through sexual contact. 

Here are some key points to know about sexually transmitted ringworm. 

Tell me more about sexually transmitted ringworm: What is causing it?

Skin-to-skin contact is a common mode of ringworm transmission. In recent years, transmission of ringworm via intimate or sexual contact has been increasingly recognized. However, clinicians may not immediately consider ringworm when evaluating genital, facial, or perianal lesions. Infections with sexually transmitted TMVII commonly cause lesions on anatomical sites that may be exposed during intimate or sexual contact, such as the face, genitals, and perianal region. Sexual transmission of TMVII has been reported in Europe, predominantly among men who have sex with men, for several years. Other dermatophyte strains have been reported in association with sexual contact, including the emerging strain Trichophyton indotineae. However, sexual transmission is not the main mode of transmission for T indotineae and other dermatophyte strains. 

When should clinicians suspect a potential case of sexually transmitted ringworm?

Providers should consider sexually transmitted ringworm when seeing ringworm in locations associated with intimate contact (for example, a rash on or around the genitals, perianal area, or mouth). 

The typical appearance of ringworm is a raised, ring-like, erythematous rash with a scaly border that grows over time. The rash may appear pink, brown, or gray on different types of skin. Patients may note itching and flaking of the rash. In areas with hair such as the beard area, ringworm can present as pustules and be associated with hair loss.

Emerging ringworm infections can present in atypical or more severe ways, including a highly inflammatory (painful, scarring, or otherwise severe) rash, a rash affecting a large area or multiple sites, nodules, and pustules. 

Sexually transmitted ringworm may be considered based on sexual history and recent sexual contact with someone with known TMVII. Recent history of travel to a region with reported sexually transmitted ringworm may increase suspicion of TMVII. In patients with a travel history to South Asia, T indotineae should be considered, especially if the rash does not improve with oral terbinafine. 

How can testing help guide the diagnosis of sexually transmitted ringworm infection?

When evaluating a rash that may represent ringworm, providers should use a confirmatory test such as potassium hydroxide (KOH) preparation when possible. KOH prep can confirm the presence of a fungus that causes ringworm, but it does not identify the species or type of ringworm. Testing such as fungal culture and molecular testing can help identify specific types of ringworm, but these tests are not often performed and may take a long time to yield results.

Routine fungal cultures cannot identify TMVII and T indotineae; these tests may identify the genus Trichophyton, but only advanced molecular testing, which is available at selected US laboratories, can identify TMVII and T indotineae. 

We recommend confirmatory testing because ringworm can easily be misdiagnosed as skin conditions such as psoriasis or eczema. The use of topical steroids can worsen a ringworm infection, so clinicians should be cautious about treating a rash with topical steroids if the etiology is unclear. Treatment should not be delayed if testing is not available. 

Clinicians who suspect a case of TMVII infection or infection with another emerging type of severe or antifungal-resistant ringworm can contact the Centers for Disease Control and Prevention (CDC) at fungaloutbreaks@cdc.gov. More details on how clinicians can pursue testing to identify emerging strains of ringworm can be found on the American Academy of Dermatology (AAD) emerging diseases task force website. 

How should clinicians treat and manage sexually transmitted ringworm? 

If TMVII infection is suspected, providers can consider starting empirical treatment with oral terbinafine. Although data are limited, experience from case series suggests that TMVII may require oral antifungal treatment because it can cause severe skin infections and often does not improve with topical antifungals. Clinicians should advise patients that they may need prolonged treatment courses until the rash resolves, with possible need for treatment courses of 6-8 weeks or longer. 

Any diagnosis of a sexually transmitted infection is an opportunity to engage patients in comprehensive sexual health services. Patients with suspected sexually transmitted ringworm should be evaluated for HIV and other sexually transmitted infections, including syphilis, chlamydia, and gonorrhea; clinicians should discuss and facilitate access to other preventive services, such as HIV pre-exposure prophylaxis if the patient is HIV negative and at risk for HIV. Patients should also notify their partner(s) about the diagnosis. 

Is sexually transmitted ringworm a public health concern? 

It is important to know that very few cases of TMVII have been reported in the United States thus far. CDC continues to monitor emerging dermatophyte strains because these types of ringworm can cause more severe or difficult-to-treat infections. Clinicians should be aware of the potential severity of sexually transmitted ringworm infections and of how diagnosis and treatment of these infections may differ from typical management of ringworm.

So far, TMVII, the dermatophyte strain most associated with spread through sexual contact, has not been documented to have antifungal resistance. More rarely, sexually transmitted ringworm may be caused by other emerging dermatophyte strains that are antifungal resistant, such as T indotineae. Itraconazole is the recommended first-line treatment for T indotineae infections. 

How can clinicians counsel patients with sexually transmitted ringworm?

Ringworm can spread with skin-to-skin contact, so patients should avoid such contact with others while they have a rash. They should also avoid sharing personal items (such as razors or towels) and clothing, and launder their clothing, towels, and bedding in a high heat cycle. 

People can reduce their risk of getting all types of ringworm infection by keeping their skin clean and dry, changing their socks and underwear daily, and wearing sandals in public locker rooms and other public spaces. People should avoid skin-to-skin contact with anyone with ringworm or an unexplained rash. Before having sex, people can check in with their partners and be aware of unexplained rashes on their partners’ bodies.

Where can clinicians go to learn more about sexually transmitted and other emerging types of ringworm?

CDC has partnered with the AAD to create set of online resources for clinicians for diagnosing and managing emerging dermatophyte infections. Clinicians who suspect or confirm antimicrobial resistant ringworm infection are also encouraged to submit cases to the AAD’s Emerging Diseases Registry. Clinicians wanting further guidance on how to manage suspected or confirmed ringworm infection with an emerging dermatophyte strain can also contact the CDC at fungaloutbreaks@cdc.gov. Useful information on emerging dermatophyte infections for providers and patients is also available on CDC’s website.

Relevant Reading

Zucker J et al. MMWR Morb Mortal Wkly Rep. 2024;73:985-988.Spivack S et al. Emerg Infect Dis. 2024;30:807-809.Jabet A et al. Emerg Infect Dis. 2023;29:1411-1414.

A version of this article appeared on Medscape.com. 

Dr Anand is Epidemic Intelligence Service Officer, Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. Dr Gold is Medical Officer, Mycotic Diseases Branch, Centers for Disease Control and Prevention. Dr Quilter is Medical Officer, Division of STD Prevention, Centers for Disease Control and Prevention. None reported any relevant conflicts of interest. 

Antimicrobial resistance (AMR) is globally recognized as one of the greatest health threats of the 21st century, responsible for 1.27 million deaths annually. “According to the WHO, if no measures are taken promptly, AMR could lead to more deaths than cancer by 2050,” Arnaud Marchant, MD, PhD, director of the European Plotkin Institute for Vaccinology at Université libre de Bruxelles (EPIV-ULB), Anderlecht, Belgium, said in an interview with MediQuality, part of the Medscape Professional Network. “This is a huge problem, and vaccination could be part of the solution.”

EPIV-ULB marked the start of the World AMR Awareness Week (November 18-24) with an event highlighting the critical role of vaccination to counter the rise for resistant pathogens. During the event, MediQuality interviewed Marchant, along with several other experts in the field.

 

Antibiotics Losing Effectiveness

Marc Van Ranst, PhD, virologist at Rega Institute KU Leuven in Leuven, Belgium, echoed Marchant’s concerns. He noted that “an increasing number of bacteria are becoming resistant to more antibiotics.” “While antibiotics were once miracle drugs, they have now stopped — or almost stopped — working against certain bacteria. Although we are discovering more effective therapies, bacterial infections are increasingly likely to worsen due to AMR.”

Van Ranst issued a stark warning: “If this trend continues, it is entirely reasonable to predict that in 25 years, some antibiotics will become useless, certain bacterial infections will be much harder to treat, and deaths will outnumber those caused by cancer. It’s worth noting, however, that as cancer treatments improve, cancer-related deaths are expected to decline, further highlighting the growing burden of AMR-related fatalities.”

 

Viruses, Vaccines, and Resistance

Van Ranst emphasized that while AMR primarily involves bacteria, viral infections and vaccination against them also play a role in addressing the issue. “When vaccines prevent illness, they reduce the need for unnecessary antibiotic use. In the past, antibiotics were frequently prescribed for respiratory infections — typically caused by viruses — leading to misuse and heightened resistance. By preventing viral infections through vaccines, we reduce inappropriate antibiotic prescriptions and, subsequently, AMR.”

 

Strategic Areas of Focus

To maximize the impact of vaccination in combating AMR, Belgium must prioritize several strategic areas, according to EPIV-ULB. “Expanding vaccination coverage for recommended vaccines is crucial to effectively preventing the spread of resistant pathogens,” said Marchant.

“Innovation and development of new vaccines are also essential, including targeted research into vaccines for infections that are currently unavoidable through other means. Enhancing epidemiological surveillance through national data collection and analysis will further clarify the impact of vaccines on AMR and inform policy decisions.”

EPIV-ULB underscored the importance of educating the public and healthcare professionals. “Public awareness is essential to addressing vaccine hesitancy by providing clear information on the importance of prevention,” Marchant explained. “Healthcare professional training must also improve, encouraging preventive practices and judicious antibiotic use. Furthermore, additional research is necessary to fill data gaps and develop predictive models that can guide vaccine development in the future.”

 

Role of Vaccination

According to EPIV-ULB, Belgium needs a strengthened national strategy to address AMR effectively. “Complementary solutions are increasingly important as antimicrobials lose efficacy and treatments become more complex,” Marchant said. “Vaccination offers a proactive and effective preventive solution, directly and indirectly reducing the spread of resistant pathogens.”

Vaccines combat AMR through various mechanisms. “They prevent diseases such as pneumococcal pneumonia and meningitis, reducing the need for antibiotics to treat these infections,” Marchant explained. “Additionally, vaccination lowers inappropriate antibiotic use by preventing viral infections, reducing the risk of overprescribing antibiotics in cases where they are unnecessary. Lastly, herd immunity from vaccination slows the circulation of resistant pathogens, limiting their spread.”

Van Ranst urged healthcare professionals to prioritize vaccinating at-risk populations as identified by Belgium’s Superior Health Council. These include the elderly with underlying conditions and pregnant women, especially for influenza vaccines. University Hospitals Leuven in Belgium, also conducts annual vaccination campaigns for its staff, combining flu and COVID vaccines to increase uptake.

 

A Global Challenge

Marc Noppen, MD, PhD, director of University Hospital Brussels, Belgium, emphasized the complexity of AMR as a global issue. “The problem isn’t solely due to human antibiotic use; it also stems from veterinary medicine, plant breeding, and animal husbandry. This is a multifactorial, worldwide issue that requires public awareness. Improved vaccination strategies are one way to address AMR, particularly in this post-COVID era of heightened skepticism toward vaccines,” he explained.

Marie-Lise Verschelden from Pfizer highlighted the need for cooperation across the healthcare sector. “Belgium is fortunate to have a fantastic ecosystem of academics, clinicians, and industry experts. Collaboration, including government involvement, is critical to advancing our efforts. At Pfizer, we continue to develop new vaccines and technologies, and the COVID crisis has reinforced the critical role of vaccination in combating AMR. Through our vaccine portfolio and ongoing developments, we are well-positioned to contribute significantly to this global challenge.”

Elisabeth Van Damme from GSK reiterated that AMR is a global issue requiring joint efforts. “Existing vaccines are underutilized. Vaccination protects against certain infectious diseases, reducing the need for antibiotics. Antibiotics, in turn, are sometimes prescribed incorrectly, especially for viral infections they cannot treat. At GSK, we are already developing new vaccines to meet future needs.”

Vaccination remains a cornerstone in the fight against AMR. As pathogens grow increasingly resistant to antibiotics, coordinated efforts and innovative vaccine development are essential to mitigating this global health crisis.

 

This story was translated and adapted from MediQuality using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article appeared on Medscape.com.

Antimicrobial resistance (AMR) is globally recognized as one of the greatest health threats of the 21st century, responsible for 1.27 million deaths annually. “According to the WHO, if no measures are taken promptly, AMR could lead to more deaths than cancer by 2050,” Arnaud Marchant, MD, PhD, director of the European Plotkin Institute for Vaccinology at Université libre de Bruxelles (EPIV-ULB), Anderlecht, Belgium, said in an interview with MediQuality, part of the Medscape Professional Network. “This is a huge problem, and vaccination could be part of the solution.”

EPIV-ULB marked the start of the World AMR Awareness Week (November 18-24) with an event highlighting the critical role of vaccination to counter the rise for resistant pathogens. During the event, MediQuality interviewed Marchant, along with several other experts in the field.

 

Antibiotics Losing Effectiveness

Marc Van Ranst, PhD, virologist at Rega Institute KU Leuven in Leuven, Belgium, echoed Marchant’s concerns. He noted that “an increasing number of bacteria are becoming resistant to more antibiotics.” “While antibiotics were once miracle drugs, they have now stopped — or almost stopped — working against certain bacteria. Although we are discovering more effective therapies, bacterial infections are increasingly likely to worsen due to AMR.”

Van Ranst issued a stark warning: “If this trend continues, it is entirely reasonable to predict that in 25 years, some antibiotics will become useless, certain bacterial infections will be much harder to treat, and deaths will outnumber those caused by cancer. It’s worth noting, however, that as cancer treatments improve, cancer-related deaths are expected to decline, further highlighting the growing burden of AMR-related fatalities.”

 

Viruses, Vaccines, and Resistance

Van Ranst emphasized that while AMR primarily involves bacteria, viral infections and vaccination against them also play a role in addressing the issue. “When vaccines prevent illness, they reduce the need for unnecessary antibiotic use. In the past, antibiotics were frequently prescribed for respiratory infections — typically caused by viruses — leading to misuse and heightened resistance. By preventing viral infections through vaccines, we reduce inappropriate antibiotic prescriptions and, subsequently, AMR.”

 

Strategic Areas of Focus

To maximize the impact of vaccination in combating AMR, Belgium must prioritize several strategic areas, according to EPIV-ULB. “Expanding vaccination coverage for recommended vaccines is crucial to effectively preventing the spread of resistant pathogens,” said Marchant.

“Innovation and development of new vaccines are also essential, including targeted research into vaccines for infections that are currently unavoidable through other means. Enhancing epidemiological surveillance through national data collection and analysis will further clarify the impact of vaccines on AMR and inform policy decisions.”

EPIV-ULB underscored the importance of educating the public and healthcare professionals. “Public awareness is essential to addressing vaccine hesitancy by providing clear information on the importance of prevention,” Marchant explained. “Healthcare professional training must also improve, encouraging preventive practices and judicious antibiotic use. Furthermore, additional research is necessary to fill data gaps and develop predictive models that can guide vaccine development in the future.”

 

Role of Vaccination

According to EPIV-ULB, Belgium needs a strengthened national strategy to address AMR effectively. “Complementary solutions are increasingly important as antimicrobials lose efficacy and treatments become more complex,” Marchant said. “Vaccination offers a proactive and effective preventive solution, directly and indirectly reducing the spread of resistant pathogens.”

Vaccines combat AMR through various mechanisms. “They prevent diseases such as pneumococcal pneumonia and meningitis, reducing the need for antibiotics to treat these infections,” Marchant explained. “Additionally, vaccination lowers inappropriate antibiotic use by preventing viral infections, reducing the risk of overprescribing antibiotics in cases where they are unnecessary. Lastly, herd immunity from vaccination slows the circulation of resistant pathogens, limiting their spread.”

Van Ranst urged healthcare professionals to prioritize vaccinating at-risk populations as identified by Belgium’s Superior Health Council. These include the elderly with underlying conditions and pregnant women, especially for influenza vaccines. University Hospitals Leuven in Belgium, also conducts annual vaccination campaigns for its staff, combining flu and COVID vaccines to increase uptake.

 

A Global Challenge

Marc Noppen, MD, PhD, director of University Hospital Brussels, Belgium, emphasized the complexity of AMR as a global issue. “The problem isn’t solely due to human antibiotic use; it also stems from veterinary medicine, plant breeding, and animal husbandry. This is a multifactorial, worldwide issue that requires public awareness. Improved vaccination strategies are one way to address AMR, particularly in this post-COVID era of heightened skepticism toward vaccines,” he explained.

Marie-Lise Verschelden from Pfizer highlighted the need for cooperation across the healthcare sector. “Belgium is fortunate to have a fantastic ecosystem of academics, clinicians, and industry experts. Collaboration, including government involvement, is critical to advancing our efforts. At Pfizer, we continue to develop new vaccines and technologies, and the COVID crisis has reinforced the critical role of vaccination in combating AMR. Through our vaccine portfolio and ongoing developments, we are well-positioned to contribute significantly to this global challenge.”

Elisabeth Van Damme from GSK reiterated that AMR is a global issue requiring joint efforts. “Existing vaccines are underutilized. Vaccination protects against certain infectious diseases, reducing the need for antibiotics. Antibiotics, in turn, are sometimes prescribed incorrectly, especially for viral infections they cannot treat. At GSK, we are already developing new vaccines to meet future needs.”

Vaccination remains a cornerstone in the fight against AMR. As pathogens grow increasingly resistant to antibiotics, coordinated efforts and innovative vaccine development are essential to mitigating this global health crisis.

 

This story was translated and adapted from MediQuality using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article appeared on Medscape.com.

Antimicrobial resistance (AMR) is globally recognized as one of the greatest health threats of the 21st century, responsible for 1.27 million deaths annually. “According to the WHO, if no measures are taken promptly, AMR could lead to more deaths than cancer by 2050,” Arnaud Marchant, MD, PhD, director of the European Plotkin Institute for Vaccinology at Université libre de Bruxelles (EPIV-ULB), Anderlecht, Belgium, said in an interview with MediQuality, part of the Medscape Professional Network. “This is a huge problem, and vaccination could be part of the solution.”

EPIV-ULB marked the start of the World AMR Awareness Week (November 18-24) with an event highlighting the critical role of vaccination to counter the rise for resistant pathogens. During the event, MediQuality interviewed Marchant, along with several other experts in the field.

 

Antibiotics Losing Effectiveness

Marc Van Ranst, PhD, virologist at Rega Institute KU Leuven in Leuven, Belgium, echoed Marchant’s concerns. He noted that “an increasing number of bacteria are becoming resistant to more antibiotics.” “While antibiotics were once miracle drugs, they have now stopped — or almost stopped — working against certain bacteria. Although we are discovering more effective therapies, bacterial infections are increasingly likely to worsen due to AMR.”

Van Ranst issued a stark warning: “If this trend continues, it is entirely reasonable to predict that in 25 years, some antibiotics will become useless, certain bacterial infections will be much harder to treat, and deaths will outnumber those caused by cancer. It’s worth noting, however, that as cancer treatments improve, cancer-related deaths are expected to decline, further highlighting the growing burden of AMR-related fatalities.”

 

Viruses, Vaccines, and Resistance

Van Ranst emphasized that while AMR primarily involves bacteria, viral infections and vaccination against them also play a role in addressing the issue. “When vaccines prevent illness, they reduce the need for unnecessary antibiotic use. In the past, antibiotics were frequently prescribed for respiratory infections — typically caused by viruses — leading to misuse and heightened resistance. By preventing viral infections through vaccines, we reduce inappropriate antibiotic prescriptions and, subsequently, AMR.”

 

Strategic Areas of Focus

To maximize the impact of vaccination in combating AMR, Belgium must prioritize several strategic areas, according to EPIV-ULB. “Expanding vaccination coverage for recommended vaccines is crucial to effectively preventing the spread of resistant pathogens,” said Marchant.

“Innovation and development of new vaccines are also essential, including targeted research into vaccines for infections that are currently unavoidable through other means. Enhancing epidemiological surveillance through national data collection and analysis will further clarify the impact of vaccines on AMR and inform policy decisions.”

EPIV-ULB underscored the importance of educating the public and healthcare professionals. “Public awareness is essential to addressing vaccine hesitancy by providing clear information on the importance of prevention,” Marchant explained. “Healthcare professional training must also improve, encouraging preventive practices and judicious antibiotic use. Furthermore, additional research is necessary to fill data gaps and develop predictive models that can guide vaccine development in the future.”

 

Role of Vaccination

According to EPIV-ULB, Belgium needs a strengthened national strategy to address AMR effectively. “Complementary solutions are increasingly important as antimicrobials lose efficacy and treatments become more complex,” Marchant said. “Vaccination offers a proactive and effective preventive solution, directly and indirectly reducing the spread of resistant pathogens.”

Vaccines combat AMR through various mechanisms. “They prevent diseases such as pneumococcal pneumonia and meningitis, reducing the need for antibiotics to treat these infections,” Marchant explained. “Additionally, vaccination lowers inappropriate antibiotic use by preventing viral infections, reducing the risk of overprescribing antibiotics in cases where they are unnecessary. Lastly, herd immunity from vaccination slows the circulation of resistant pathogens, limiting their spread.”

Van Ranst urged healthcare professionals to prioritize vaccinating at-risk populations as identified by Belgium’s Superior Health Council. These include the elderly with underlying conditions and pregnant women, especially for influenza vaccines. University Hospitals Leuven in Belgium, also conducts annual vaccination campaigns for its staff, combining flu and COVID vaccines to increase uptake.

 

A Global Challenge

Marc Noppen, MD, PhD, director of University Hospital Brussels, Belgium, emphasized the complexity of AMR as a global issue. “The problem isn’t solely due to human antibiotic use; it also stems from veterinary medicine, plant breeding, and animal husbandry. This is a multifactorial, worldwide issue that requires public awareness. Improved vaccination strategies are one way to address AMR, particularly in this post-COVID era of heightened skepticism toward vaccines,” he explained.

Marie-Lise Verschelden from Pfizer highlighted the need for cooperation across the healthcare sector. “Belgium is fortunate to have a fantastic ecosystem of academics, clinicians, and industry experts. Collaboration, including government involvement, is critical to advancing our efforts. At Pfizer, we continue to develop new vaccines and technologies, and the COVID crisis has reinforced the critical role of vaccination in combating AMR. Through our vaccine portfolio and ongoing developments, we are well-positioned to contribute significantly to this global challenge.”

Elisabeth Van Damme from GSK reiterated that AMR is a global issue requiring joint efforts. “Existing vaccines are underutilized. Vaccination protects against certain infectious diseases, reducing the need for antibiotics. Antibiotics, in turn, are sometimes prescribed incorrectly, especially for viral infections they cannot treat. At GSK, we are already developing new vaccines to meet future needs.”

Vaccination remains a cornerstone in the fight against AMR. As pathogens grow increasingly resistant to antibiotics, coordinated efforts and innovative vaccine development are essential to mitigating this global health crisis.

 

This story was translated and adapted from MediQuality using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article appeared on Medscape.com.

The United States Preventive Services Task Force (USPSTF) has issued an updated draft recommendation statement advising early screening for syphilis in all pregnant persons with no signs or symptoms of syphilis, regardless of risk. Those with abnormal screening results should receive “timely, equitable, and evidence-based evaluation and treatment for syphilis,” it advises.

Reaffirming the task force’s 2018 statement, in which an evidence review found the benefits of screening substantially outweighed the harms, the current draft is based on no substantial new data. It is open for public input until December 23.

“Congenital syphilis infection is still an important health problem, and rates are not decreasing as they should,” said USPSTF panel member Carlos R. Jaén, MD, PhD, MS, Dr. and Mrs. James L. Holly Distinguished Chair in the Department of Family and Community Medicine at the Joe R. and Teresa Lozano Long School of Medicine at the University of Texas Health Science Center at San Antonio. “Cases are 10 times higher today than they were a decade ago, despite the harmful consequences of syphilis infection in mother and baby and despite it being a preventable and easily treated condition.”

The statement notes that untreated syphilis infection in mothers is associated with miscarriage, premature birth, low birth weight, stillbirth, and neonatal death. Syphilis infection is linked to significant abnormalities in infants such as deformed bones, anemia, enlarged liver and spleen, jaundice, meningitis, and brain and nerve problems resulting in permanent vision or hearing loss.

The USPSTF statement aligns with the recommendations of other healthcare organizations, including the American College of Obstetricians and Gynecologists (ACOG), which issued a clinical practice advisory on prenatal syphilis screening in April 2024.

This advisory recommends obstetric care providers screen all pregnant individuals serologically for syphilis at the first prenatal care visit, with universal rescreening during the third trimester and at birth rather than targeted risk-based testing.

The advisory notes that two in five infants with congenital syphilis were born to persons who received no prenatal care. It urges making any healthcare encounter during pregnancy — in emergency departments, jails, syringe service programs, and maternal and child health clinics — an opportunity to screen for syphilis.

So far, there is no official guidance on preconception screening for persons planning a pregnancy, according to Allison Bryant Mantha, MD, MPH, a maternal-fetal medicine specialist at Mass General Brigham health system and an associate professor at Harvard School of Medicine in Boston, Massachusetts, who coauthored the ACOG advisory.

But Lynn M. Yee, MD, MPH, an associate professor of maternal-fetal medicine at Northwestern University Feinberg School of Medicine and director of the Northwestern Medicine Women’s Infectious Disease Program in Chicago, Illinois, said syphilis testing could easily be part of a prepregnancy “bucket” of health checkup items along with other sexually transmitted infections and blood pressure.

 

By the Numbers

In 2022, there were 3761 cases of congenital syphilis in the United States, including 231 stillbirths and 51 infant deaths — the highest number reported in more than 30 years and more than 10 times that reported in 2012.

At play may be social, economic, and immigration status factors creating barriers to prenatal care as well as declines in prevention infrastructure and resources.

Although most syphilis cases occur in men, the increase in incidence rate in women was two to four times higher than that of men from 2017 to 2021.

 

Why Such Persistently High Rates?

Despite a widely available test and cost-effective penicillin treatment covered by most insurance, congenital syphilis remains a challenge. According to Bryant, many mothers are still presenting for care and testing late in pregnancy. “Differential access to care is just one of many reasons,” she said.

Stigma and bias may also play a part, according to Yee. “Some clinicians may think their patient population is not the kind to be at risk and doesn’t need to be screened,” she said. Furthermore, screening is not a one-off test but a two-step process, and serology results can be hard to understand and easy to misinterpret.

In addition, some situations may promote ongoing disease, according to Yee. “Reinfection can occur after treatment if a patient keeps returning to a partner who refuses treatment,” Yee said.

On an optimistic note, however, the Centers for Disease Control and Prevention (CDC) reports that in some areas increases in newborn syphilis cases appear to be slowing — with a 3% increase in 2022 than with a 30% or higher annual increases in previous years. In 2020-2021, for example, congenital cases rose by 32% and resulted in 220 stillbirths and infant deaths.

 

Going Forward

The USPSTF statement identifies knowledge gaps. These include studies to evaluate the benefits and harms of repeat screening later in pregnancy and to evaluate the benefits and harms of such strategies as rapid point-of-care tests. The USPSTF also called for research on disparities in syphilis incidence and screening rates to reduce these disparities in populations.

Within these vulnerable groups, the CDC noted that babies born to Black, Hispanic, or Native American/Alaska Native mothers in 2021 were as much as eight times more likely to have congenital syphilis than those born to their White counterparts.

Jaén, Bryant, and Yee had no competing interests relevant to their comments.

A version of this article appeared on Medscape.com.

The United States Preventive Services Task Force (USPSTF) has issued an updated draft recommendation statement advising early screening for syphilis in all pregnant persons with no signs or symptoms of syphilis, regardless of risk. Those with abnormal screening results should receive “timely, equitable, and evidence-based evaluation and treatment for syphilis,” it advises.

Reaffirming the task force’s 2018 statement, in which an evidence review found the benefits of screening substantially outweighed the harms, the current draft is based on no substantial new data. It is open for public input until December 23.

“Congenital syphilis infection is still an important health problem, and rates are not decreasing as they should,” said USPSTF panel member Carlos R. Jaén, MD, PhD, MS, Dr. and Mrs. James L. Holly Distinguished Chair in the Department of Family and Community Medicine at the Joe R. and Teresa Lozano Long School of Medicine at the University of Texas Health Science Center at San Antonio. “Cases are 10 times higher today than they were a decade ago, despite the harmful consequences of syphilis infection in mother and baby and despite it being a preventable and easily treated condition.”

The statement notes that untreated syphilis infection in mothers is associated with miscarriage, premature birth, low birth weight, stillbirth, and neonatal death. Syphilis infection is linked to significant abnormalities in infants such as deformed bones, anemia, enlarged liver and spleen, jaundice, meningitis, and brain and nerve problems resulting in permanent vision or hearing loss.

The USPSTF statement aligns with the recommendations of other healthcare organizations, including the American College of Obstetricians and Gynecologists (ACOG), which issued a clinical practice advisory on prenatal syphilis screening in April 2024.

This advisory recommends obstetric care providers screen all pregnant individuals serologically for syphilis at the first prenatal care visit, with universal rescreening during the third trimester and at birth rather than targeted risk-based testing.

The advisory notes that two in five infants with congenital syphilis were born to persons who received no prenatal care. It urges making any healthcare encounter during pregnancy — in emergency departments, jails, syringe service programs, and maternal and child health clinics — an opportunity to screen for syphilis.

So far, there is no official guidance on preconception screening for persons planning a pregnancy, according to Allison Bryant Mantha, MD, MPH, a maternal-fetal medicine specialist at Mass General Brigham health system and an associate professor at Harvard School of Medicine in Boston, Massachusetts, who coauthored the ACOG advisory.

But Lynn M. Yee, MD, MPH, an associate professor of maternal-fetal medicine at Northwestern University Feinberg School of Medicine and director of the Northwestern Medicine Women’s Infectious Disease Program in Chicago, Illinois, said syphilis testing could easily be part of a prepregnancy “bucket” of health checkup items along with other sexually transmitted infections and blood pressure.

 

By the Numbers

In 2022, there were 3761 cases of congenital syphilis in the United States, including 231 stillbirths and 51 infant deaths — the highest number reported in more than 30 years and more than 10 times that reported in 2012.

At play may be social, economic, and immigration status factors creating barriers to prenatal care as well as declines in prevention infrastructure and resources.

Although most syphilis cases occur in men, the increase in incidence rate in women was two to four times higher than that of men from 2017 to 2021.

 

Why Such Persistently High Rates?

Despite a widely available test and cost-effective penicillin treatment covered by most insurance, congenital syphilis remains a challenge. According to Bryant, many mothers are still presenting for care and testing late in pregnancy. “Differential access to care is just one of many reasons,” she said.

Stigma and bias may also play a part, according to Yee. “Some clinicians may think their patient population is not the kind to be at risk and doesn’t need to be screened,” she said. Furthermore, screening is not a one-off test but a two-step process, and serology results can be hard to understand and easy to misinterpret.

In addition, some situations may promote ongoing disease, according to Yee. “Reinfection can occur after treatment if a patient keeps returning to a partner who refuses treatment,” Yee said.

On an optimistic note, however, the Centers for Disease Control and Prevention (CDC) reports that in some areas increases in newborn syphilis cases appear to be slowing — with a 3% increase in 2022 than with a 30% or higher annual increases in previous years. In 2020-2021, for example, congenital cases rose by 32% and resulted in 220 stillbirths and infant deaths.

 

Going Forward

The USPSTF statement identifies knowledge gaps. These include studies to evaluate the benefits and harms of repeat screening later in pregnancy and to evaluate the benefits and harms of such strategies as rapid point-of-care tests. The USPSTF also called for research on disparities in syphilis incidence and screening rates to reduce these disparities in populations.

Within these vulnerable groups, the CDC noted that babies born to Black, Hispanic, or Native American/Alaska Native mothers in 2021 were as much as eight times more likely to have congenital syphilis than those born to their White counterparts.

Jaén, Bryant, and Yee had no competing interests relevant to their comments.

A version of this article appeared on Medscape.com.

The United States Preventive Services Task Force (USPSTF) has issued an updated draft recommendation statement advising early screening for syphilis in all pregnant persons with no signs or symptoms of syphilis, regardless of risk. Those with abnormal screening results should receive “timely, equitable, and evidence-based evaluation and treatment for syphilis,” it advises.

Reaffirming the task force’s 2018 statement, in which an evidence review found the benefits of screening substantially outweighed the harms, the current draft is based on no substantial new data. It is open for public input until December 23.

“Congenital syphilis infection is still an important health problem, and rates are not decreasing as they should,” said USPSTF panel member Carlos R. Jaén, MD, PhD, MS, Dr. and Mrs. James L. Holly Distinguished Chair in the Department of Family and Community Medicine at the Joe R. and Teresa Lozano Long School of Medicine at the University of Texas Health Science Center at San Antonio. “Cases are 10 times higher today than they were a decade ago, despite the harmful consequences of syphilis infection in mother and baby and despite it being a preventable and easily treated condition.”

The statement notes that untreated syphilis infection in mothers is associated with miscarriage, premature birth, low birth weight, stillbirth, and neonatal death. Syphilis infection is linked to significant abnormalities in infants such as deformed bones, anemia, enlarged liver and spleen, jaundice, meningitis, and brain and nerve problems resulting in permanent vision or hearing loss.

The USPSTF statement aligns with the recommendations of other healthcare organizations, including the American College of Obstetricians and Gynecologists (ACOG), which issued a clinical practice advisory on prenatal syphilis screening in April 2024.

This advisory recommends obstetric care providers screen all pregnant individuals serologically for syphilis at the first prenatal care visit, with universal rescreening during the third trimester and at birth rather than targeted risk-based testing.

The advisory notes that two in five infants with congenital syphilis were born to persons who received no prenatal care. It urges making any healthcare encounter during pregnancy — in emergency departments, jails, syringe service programs, and maternal and child health clinics — an opportunity to screen for syphilis.

So far, there is no official guidance on preconception screening for persons planning a pregnancy, according to Allison Bryant Mantha, MD, MPH, a maternal-fetal medicine specialist at Mass General Brigham health system and an associate professor at Harvard School of Medicine in Boston, Massachusetts, who coauthored the ACOG advisory.

But Lynn M. Yee, MD, MPH, an associate professor of maternal-fetal medicine at Northwestern University Feinberg School of Medicine and director of the Northwestern Medicine Women’s Infectious Disease Program in Chicago, Illinois, said syphilis testing could easily be part of a prepregnancy “bucket” of health checkup items along with other sexually transmitted infections and blood pressure.

 

By the Numbers

In 2022, there were 3761 cases of congenital syphilis in the United States, including 231 stillbirths and 51 infant deaths — the highest number reported in more than 30 years and more than 10 times that reported in 2012.

At play may be social, economic, and immigration status factors creating barriers to prenatal care as well as declines in prevention infrastructure and resources.

Although most syphilis cases occur in men, the increase in incidence rate in women was two to four times higher than that of men from 2017 to 2021.

 

Why Such Persistently High Rates?

Despite a widely available test and cost-effective penicillin treatment covered by most insurance, congenital syphilis remains a challenge. According to Bryant, many mothers are still presenting for care and testing late in pregnancy. “Differential access to care is just one of many reasons,” she said.

Stigma and bias may also play a part, according to Yee. “Some clinicians may think their patient population is not the kind to be at risk and doesn’t need to be screened,” she said. Furthermore, screening is not a one-off test but a two-step process, and serology results can be hard to understand and easy to misinterpret.

In addition, some situations may promote ongoing disease, according to Yee. “Reinfection can occur after treatment if a patient keeps returning to a partner who refuses treatment,” Yee said.

On an optimistic note, however, the Centers for Disease Control and Prevention (CDC) reports that in some areas increases in newborn syphilis cases appear to be slowing — with a 3% increase in 2022 than with a 30% or higher annual increases in previous years. In 2020-2021, for example, congenital cases rose by 32% and resulted in 220 stillbirths and infant deaths.

 

Going Forward

The USPSTF statement identifies knowledge gaps. These include studies to evaluate the benefits and harms of repeat screening later in pregnancy and to evaluate the benefits and harms of such strategies as rapid point-of-care tests. The USPSTF also called for research on disparities in syphilis incidence and screening rates to reduce these disparities in populations.

Within these vulnerable groups, the CDC noted that babies born to Black, Hispanic, or Native American/Alaska Native mothers in 2021 were as much as eight times more likely to have congenital syphilis than those born to their White counterparts.

Jaén, Bryant, and Yee had no competing interests relevant to their comments.

A version of this article appeared on Medscape.com.

The persistent epidemic of sexually transmitted infections (STIs) in the United States is showing signs of a slowdown in cases of syphilis, gonorrhea, and chlamydia, according to the latest data from the Centers for Disease Control and Prevention (CDC).

More than 2.4 million cases of these three nationally notifiable STIs were reported in the United States in 2023 but represent a 1.8% decrease from 2022, based on a new CDC report, Sexually Transmitted Infections Surveillance, 2023.

The 2023 report indicates a 7.2% decrease in gonorrhea, which accounts for most of the decrease.

Although syphilis cases increased overall, they did so by only 1% compared with double-digit increases in previous years, according to the report. Primary and secondary syphilis decreased by 10%, compared with 2022 overall, with a 13% decrease in cases among gay and bisexual men.

Congenital syphilis rates increased by 3%. However, the 3% increase represents a significant drop from the 30% increases each year in recent years, according to the report.

Chlamydia rates remained essentially stable, with a decrease of less than 1.0% overall. Reported chlamydia rates increased by 1.3% among men and decreased by 1.7% among women.

Despite the declines, overall disparities persist, with higher rates of STIs among gay and bisexual men, as well as American Indian/Alaska Native, Black/African American, and Hispanic/Latino populations, according to the report.

 

CDC Cautiously Optimistic

The CDC is “guardedly optimistic that the new data represent a turning point in terms of syphilis and gonorrhea,” said Bradley Stoner, MD, director of the CDC’s Division of STD Prevention, in an interview.

However, a tremendous amount of work remains to be done, notably in addressing disparities in care, said Stoner.

New techniques for diagnosis and treatment, such as the increased use of doxycycline (doxy PEP) for the prevention of STIs after sex for high-risk populations with a history of STIs, are likely contributing to the overall decrease, Stoner said. Other contributing factors include improved communication and awareness of STI treatment options at the community level in emergency departments, substance use facilities, and syringe use programs.

Although the United States has not yet turned the corner in reducing STIs, “We are at an inflection point in the epidemic after years of increases,” Stoner told this news organization. “The CDC is committed to keeping the momentum going and turning things around.” Although congenital syphilis rates are slowing down, it remains a significant problem with severe outcomes for mothers and infants, he noted.

The message to healthcare providers on the front lines is to increase awareness, screen widely, and provide effective treatments, Stoner emphasized.

Looking ahead, more research is needed to identify the settings in which prevention tools can be best utilized, such as urgent care or other programs, said Stoner. “My hope is that implementation science research will give us some clues.” In addition, better tools for detection and treatment of STIs are always needed, notably better diagnostics for syphilis, which still requires a blood test, although research is underway for more efficient testing.

 

Spotlight on Disparities, Syphilis

“I think these are very nuanced results,” said David J. Cennimo, MD, associate professor of medicine and pediatrics in the Division of Infectious Disease at Rutgers New Jersey Medical School, Newark, in an interview. “I am happy, on first pass, to see that STI rates have declined.” However, a closer look reveals that most of the improvements are driven by the 7% drop in gonorrhea, while chlamydia and syphilis rates are relatively stable.

The decreases may reflect that the public is receiving the messaging about the need for screening and safer sex. “Clinicians also have been educated on the need for screening,” Cennimo said. However, “we are still 90% above the [STI] rates from 20 years ago.”

Clinicians also must recognize the disparities in STI rates by race and other demographics, Cennimo said. The current report “is a call to make sure that STI and other medical services are targeted to specific groups as needed and are widely available, especially in under-resourced areas.”

“I am still dismayed by the high syphilis rates, which are also resulting in congenital syphilis,” Cennimo said. “Syphilis in pregnancy is very dangerous, and any case of congenital syphilis is a failure of preventive care and screening; it is a potentially devastating disease.

“We have good treatments for STIs, but we must continue to monitor for resistance,” said Cennimo. “More work is needed to reach high-risk individuals and to provide preventive care and screening.” 

The research was supported by the CDC. Stoner and Cennimo had no financial conflicts to disclose.

A version of this article first appeared on Medscape.com.

The persistent epidemic of sexually transmitted infections (STIs) in the United States is showing signs of a slowdown in cases of syphilis, gonorrhea, and chlamydia, according to the latest data from the Centers for Disease Control and Prevention (CDC).

More than 2.4 million cases of these three nationally notifiable STIs were reported in the United States in 2023 but represent a 1.8% decrease from 2022, based on a new CDC report, Sexually Transmitted Infections Surveillance, 2023.

The 2023 report indicates a 7.2% decrease in gonorrhea, which accounts for most of the decrease.

Although syphilis cases increased overall, they did so by only 1% compared with double-digit increases in previous years, according to the report. Primary and secondary syphilis decreased by 10%, compared with 2022 overall, with a 13% decrease in cases among gay and bisexual men.

Congenital syphilis rates increased by 3%. However, the 3% increase represents a significant drop from the 30% increases each year in recent years, according to the report.

Chlamydia rates remained essentially stable, with a decrease of less than 1.0% overall. Reported chlamydia rates increased by 1.3% among men and decreased by 1.7% among women.

Despite the declines, overall disparities persist, with higher rates of STIs among gay and bisexual men, as well as American Indian/Alaska Native, Black/African American, and Hispanic/Latino populations, according to the report.

 

CDC Cautiously Optimistic

The CDC is “guardedly optimistic that the new data represent a turning point in terms of syphilis and gonorrhea,” said Bradley Stoner, MD, director of the CDC’s Division of STD Prevention, in an interview.

However, a tremendous amount of work remains to be done, notably in addressing disparities in care, said Stoner.

New techniques for diagnosis and treatment, such as the increased use of doxycycline (doxy PEP) for the prevention of STIs after sex for high-risk populations with a history of STIs, are likely contributing to the overall decrease, Stoner said. Other contributing factors include improved communication and awareness of STI treatment options at the community level in emergency departments, substance use facilities, and syringe use programs.

Although the United States has not yet turned the corner in reducing STIs, “We are at an inflection point in the epidemic after years of increases,” Stoner told this news organization. “The CDC is committed to keeping the momentum going and turning things around.” Although congenital syphilis rates are slowing down, it remains a significant problem with severe outcomes for mothers and infants, he noted.

The message to healthcare providers on the front lines is to increase awareness, screen widely, and provide effective treatments, Stoner emphasized.

Looking ahead, more research is needed to identify the settings in which prevention tools can be best utilized, such as urgent care or other programs, said Stoner. “My hope is that implementation science research will give us some clues.” In addition, better tools for detection and treatment of STIs are always needed, notably better diagnostics for syphilis, which still requires a blood test, although research is underway for more efficient testing.

 

Spotlight on Disparities, Syphilis

“I think these are very nuanced results,” said David J. Cennimo, MD, associate professor of medicine and pediatrics in the Division of Infectious Disease at Rutgers New Jersey Medical School, Newark, in an interview. “I am happy, on first pass, to see that STI rates have declined.” However, a closer look reveals that most of the improvements are driven by the 7% drop in gonorrhea, while chlamydia and syphilis rates are relatively stable.

The decreases may reflect that the public is receiving the messaging about the need for screening and safer sex. “Clinicians also have been educated on the need for screening,” Cennimo said. However, “we are still 90% above the [STI] rates from 20 years ago.”

Clinicians also must recognize the disparities in STI rates by race and other demographics, Cennimo said. The current report “is a call to make sure that STI and other medical services are targeted to specific groups as needed and are widely available, especially in under-resourced areas.”

“I am still dismayed by the high syphilis rates, which are also resulting in congenital syphilis,” Cennimo said. “Syphilis in pregnancy is very dangerous, and any case of congenital syphilis is a failure of preventive care and screening; it is a potentially devastating disease.

“We have good treatments for STIs, but we must continue to monitor for resistance,” said Cennimo. “More work is needed to reach high-risk individuals and to provide preventive care and screening.” 

The research was supported by the CDC. Stoner and Cennimo had no financial conflicts to disclose.

A version of this article first appeared on Medscape.com.

The persistent epidemic of sexually transmitted infections (STIs) in the United States is showing signs of a slowdown in cases of syphilis, gonorrhea, and chlamydia, according to the latest data from the Centers for Disease Control and Prevention (CDC).

More than 2.4 million cases of these three nationally notifiable STIs were reported in the United States in 2023 but represent a 1.8% decrease from 2022, based on a new CDC report, Sexually Transmitted Infections Surveillance, 2023.

The 2023 report indicates a 7.2% decrease in gonorrhea, which accounts for most of the decrease.

Although syphilis cases increased overall, they did so by only 1% compared with double-digit increases in previous years, according to the report. Primary and secondary syphilis decreased by 10%, compared with 2022 overall, with a 13% decrease in cases among gay and bisexual men.

Congenital syphilis rates increased by 3%. However, the 3% increase represents a significant drop from the 30% increases each year in recent years, according to the report.

Chlamydia rates remained essentially stable, with a decrease of less than 1.0% overall. Reported chlamydia rates increased by 1.3% among men and decreased by 1.7% among women.

Despite the declines, overall disparities persist, with higher rates of STIs among gay and bisexual men, as well as American Indian/Alaska Native, Black/African American, and Hispanic/Latino populations, according to the report.

 

CDC Cautiously Optimistic

The CDC is “guardedly optimistic that the new data represent a turning point in terms of syphilis and gonorrhea,” said Bradley Stoner, MD, director of the CDC’s Division of STD Prevention, in an interview.

However, a tremendous amount of work remains to be done, notably in addressing disparities in care, said Stoner.

New techniques for diagnosis and treatment, such as the increased use of doxycycline (doxy PEP) for the prevention of STIs after sex for high-risk populations with a history of STIs, are likely contributing to the overall decrease, Stoner said. Other contributing factors include improved communication and awareness of STI treatment options at the community level in emergency departments, substance use facilities, and syringe use programs.

Although the United States has not yet turned the corner in reducing STIs, “We are at an inflection point in the epidemic after years of increases,” Stoner told this news organization. “The CDC is committed to keeping the momentum going and turning things around.” Although congenital syphilis rates are slowing down, it remains a significant problem with severe outcomes for mothers and infants, he noted.

The message to healthcare providers on the front lines is to increase awareness, screen widely, and provide effective treatments, Stoner emphasized.

Looking ahead, more research is needed to identify the settings in which prevention tools can be best utilized, such as urgent care or other programs, said Stoner. “My hope is that implementation science research will give us some clues.” In addition, better tools for detection and treatment of STIs are always needed, notably better diagnostics for syphilis, which still requires a blood test, although research is underway for more efficient testing.

 

Spotlight on Disparities, Syphilis

“I think these are very nuanced results,” said David J. Cennimo, MD, associate professor of medicine and pediatrics in the Division of Infectious Disease at Rutgers New Jersey Medical School, Newark, in an interview. “I am happy, on first pass, to see that STI rates have declined.” However, a closer look reveals that most of the improvements are driven by the 7% drop in gonorrhea, while chlamydia and syphilis rates are relatively stable.

The decreases may reflect that the public is receiving the messaging about the need for screening and safer sex. “Clinicians also have been educated on the need for screening,” Cennimo said. However, “we are still 90% above the [STI] rates from 20 years ago.”

Clinicians also must recognize the disparities in STI rates by race and other demographics, Cennimo said. The current report “is a call to make sure that STI and other medical services are targeted to specific groups as needed and are widely available, especially in under-resourced areas.”

“I am still dismayed by the high syphilis rates, which are also resulting in congenital syphilis,” Cennimo said. “Syphilis in pregnancy is very dangerous, and any case of congenital syphilis is a failure of preventive care and screening; it is a potentially devastating disease.

“We have good treatments for STIs, but we must continue to monitor for resistance,” said Cennimo. “More work is needed to reach high-risk individuals and to provide preventive care and screening.” 

The research was supported by the CDC. Stoner and Cennimo had no financial conflicts to disclose.

A version of this article first appeared on Medscape.com.

A dermatophyte known as Trichophyton mentagrophytes genotype VII (TMVII) has been identified as the cause of an emerging sexually transmitted fungal infection in four adults in the United States, according to a paper published in the Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report.

TMVII is a sexually transmitted fungus that causes genital tinea; the fungus might be misidentified as eczema, psoriasis, or other dermatologic conditions, Jason E. Zucker, MD, an infectious disease specialist at Columbia University Irving Medical Center, New York City, and colleagues wrote.

 

“Dermatophyte infections, including TMVII, are spread through direct skin-to-skin contact,” corresponding author Avrom S. Caplan, MD, a dermatologist at New York University Grossman School of Medicine, New York City, said in an interview.

“In the United States, to our knowledge, the infection has only been in MSM [men who have sex with men], but there have been reports of TMVII in Europe in non-MSM patients, including among patients who traveled to Southeast Asia for sex tourism or partners of people who have been infected with TMVII,” he said.

The four patients were diagnosed with tinea between April 2024 and July 2024, and fungal cultures and DNA sequencing identified TMVII as the cause of the infection. All four patients were cisgender men aged 30-39 years from New York City who reported recent sexual contact with other men; one was a sex worker, two had sex with each other, and one reported recent travel to Europe.

All four patients presented with rashes on the face, buttocks, or genitals; all were successfully treated with antifungals, the authors wrote.

Individuals with genital lesions who are sexually active should be seen by a healthcare provider, and TMVII should be considered, especially in the event of scaly, itchy, or inflamed rashes elsewhere on the body, Caplan told this news organization.

Additionally, “If someone presents for a medical evaluation and has ringworm on the buttocks, face, or elsewhere, especially if they are sexually active, the question of TMVII should arise, and the patient should be asked about possible genital lesions as well,” he said. “Any patient diagnosed with an STI [sexually transmitted infection], including MSM patients, should be evaluated appropriately for other STIs including TMVII.” 

Continued surveillance and monitoring are needed to track TMVII and to better understand emerging infections, Caplan told this news organization. Clinicians can find more information and a dermatophyte registry via the American Academy of Dermatology websites on emerging diseases in general and dermatophytes in particular.

“We also need better access to testing and more rapid confirmatory testing to detect emerging dermatophyte strains and monitor antifungal resistance patterns,” Caplan added. “At this time, we do not have evidence to suggest there is antifungal resistance in TMVII, which also distinguishes it from T indotineae.” 

 

Encourage Reporting and Identify New Infections

“Emerging infections can mimic noninfectious disease processes, which can make the diagnosis challenging,” Shirin A. Mazumder, MD, associate professor and infectious disease specialist at the University of Tennessee Health Science Center, Memphis, said in an interview.

“Monitoring emerging infections can be difficult if the cases are not reported and if the disease is not widespread,” Mazumder noted. Educating clinicians with case reports and encouraging them to report unusual cases to public health helps to overcome this challenge.

In the clinical setting, skin lesions that fail to respond or worsen with the application of topical steroids could be a red flag for TMVII, Mazumder told this news organization. “Since the skin findings of TMVII can closely resemble noninfectious processes such as eczema or psoriasis, the use of topical corticosteroids may have already been tried before the diagnosis of TMVII is considered.” 

Also, location matters in making the diagnosis. TMVII lesions occur on the face, genitals, extremities, trunk, and buttocks. Obtaining a thorough sexual history is important because the fungus spreads from close contact through sexual exposure, Mazumder added.

The most effective treatment for TMVII infections remains to be determined, Mazumder said. “Treatment considerations such as combination treatment with oral and topical antifungal medications vs oral antifungal medication alone is something that needs further research along with the best treatment duration.”

“Determining the rate of transmissibility between contacts, when someone is considered to be the most infectious, how long someone is considered infectious once infected, and rates of reinfection are questions that may benefit from further study,” she added.

Although the current cases are reported in MSM, determining how TMVII affects other patient populations will be interesting as more cases are reported, said Mazumder. “Further understanding of how different degrees of immunosuppression affect TMVII disease course is another important consideration.” 

Finally, determining the rate of long-term sequelae from TMVII infection and the rate of bacterial co-infection will help better understand TMVII, she said.

The researchers had no financial conflicts to disclose. Mazumder had no financial conflicts to disclose.

A version of this article first appeared on Medscape.com.

A dermatophyte known as Trichophyton mentagrophytes genotype VII (TMVII) has been identified as the cause of an emerging sexually transmitted fungal infection in four adults in the United States, according to a paper published in the Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report.

TMVII is a sexually transmitted fungus that causes genital tinea; the fungus might be misidentified as eczema, psoriasis, or other dermatologic conditions, Jason E. Zucker, MD, an infectious disease specialist at Columbia University Irving Medical Center, New York City, and colleagues wrote.

 

“Dermatophyte infections, including TMVII, are spread through direct skin-to-skin contact,” corresponding author Avrom S. Caplan, MD, a dermatologist at New York University Grossman School of Medicine, New York City, said in an interview.

“In the United States, to our knowledge, the infection has only been in MSM [men who have sex with men], but there have been reports of TMVII in Europe in non-MSM patients, including among patients who traveled to Southeast Asia for sex tourism or partners of people who have been infected with TMVII,” he said.

The four patients were diagnosed with tinea between April 2024 and July 2024, and fungal cultures and DNA sequencing identified TMVII as the cause of the infection. All four patients were cisgender men aged 30-39 years from New York City who reported recent sexual contact with other men; one was a sex worker, two had sex with each other, and one reported recent travel to Europe.

All four patients presented with rashes on the face, buttocks, or genitals; all were successfully treated with antifungals, the authors wrote.

Individuals with genital lesions who are sexually active should be seen by a healthcare provider, and TMVII should be considered, especially in the event of scaly, itchy, or inflamed rashes elsewhere on the body, Caplan told this news organization.

Additionally, “If someone presents for a medical evaluation and has ringworm on the buttocks, face, or elsewhere, especially if they are sexually active, the question of TMVII should arise, and the patient should be asked about possible genital lesions as well,” he said. “Any patient diagnosed with an STI [sexually transmitted infection], including MSM patients, should be evaluated appropriately for other STIs including TMVII.” 

Continued surveillance and monitoring are needed to track TMVII and to better understand emerging infections, Caplan told this news organization. Clinicians can find more information and a dermatophyte registry via the American Academy of Dermatology websites on emerging diseases in general and dermatophytes in particular.

“We also need better access to testing and more rapid confirmatory testing to detect emerging dermatophyte strains and monitor antifungal resistance patterns,” Caplan added. “At this time, we do not have evidence to suggest there is antifungal resistance in TMVII, which also distinguishes it from T indotineae.” 

 

Encourage Reporting and Identify New Infections

“Emerging infections can mimic noninfectious disease processes, which can make the diagnosis challenging,” Shirin A. Mazumder, MD, associate professor and infectious disease specialist at the University of Tennessee Health Science Center, Memphis, said in an interview.

“Monitoring emerging infections can be difficult if the cases are not reported and if the disease is not widespread,” Mazumder noted. Educating clinicians with case reports and encouraging them to report unusual cases to public health helps to overcome this challenge.

In the clinical setting, skin lesions that fail to respond or worsen with the application of topical steroids could be a red flag for TMVII, Mazumder told this news organization. “Since the skin findings of TMVII can closely resemble noninfectious processes such as eczema or psoriasis, the use of topical corticosteroids may have already been tried before the diagnosis of TMVII is considered.” 

Also, location matters in making the diagnosis. TMVII lesions occur on the face, genitals, extremities, trunk, and buttocks. Obtaining a thorough sexual history is important because the fungus spreads from close contact through sexual exposure, Mazumder added.

The most effective treatment for TMVII infections remains to be determined, Mazumder said. “Treatment considerations such as combination treatment with oral and topical antifungal medications vs oral antifungal medication alone is something that needs further research along with the best treatment duration.”

“Determining the rate of transmissibility between contacts, when someone is considered to be the most infectious, how long someone is considered infectious once infected, and rates of reinfection are questions that may benefit from further study,” she added.

Although the current cases are reported in MSM, determining how TMVII affects other patient populations will be interesting as more cases are reported, said Mazumder. “Further understanding of how different degrees of immunosuppression affect TMVII disease course is another important consideration.” 

Finally, determining the rate of long-term sequelae from TMVII infection and the rate of bacterial co-infection will help better understand TMVII, she said.

The researchers had no financial conflicts to disclose. Mazumder had no financial conflicts to disclose.

A version of this article first appeared on Medscape.com.

A dermatophyte known as Trichophyton mentagrophytes genotype VII (TMVII) has been identified as the cause of an emerging sexually transmitted fungal infection in four adults in the United States, according to a paper published in the Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report.

TMVII is a sexually transmitted fungus that causes genital tinea; the fungus might be misidentified as eczema, psoriasis, or other dermatologic conditions, Jason E. Zucker, MD, an infectious disease specialist at Columbia University Irving Medical Center, New York City, and colleagues wrote.

 

“Dermatophyte infections, including TMVII, are spread through direct skin-to-skin contact,” corresponding author Avrom S. Caplan, MD, a dermatologist at New York University Grossman School of Medicine, New York City, said in an interview.

“In the United States, to our knowledge, the infection has only been in MSM [men who have sex with men], but there have been reports of TMVII in Europe in non-MSM patients, including among patients who traveled to Southeast Asia for sex tourism or partners of people who have been infected with TMVII,” he said.

The four patients were diagnosed with tinea between April 2024 and July 2024, and fungal cultures and DNA sequencing identified TMVII as the cause of the infection. All four patients were cisgender men aged 30-39 years from New York City who reported recent sexual contact with other men; one was a sex worker, two had sex with each other, and one reported recent travel to Europe.

All four patients presented with rashes on the face, buttocks, or genitals; all were successfully treated with antifungals, the authors wrote.

Individuals with genital lesions who are sexually active should be seen by a healthcare provider, and TMVII should be considered, especially in the event of scaly, itchy, or inflamed rashes elsewhere on the body, Caplan told this news organization.

Additionally, “If someone presents for a medical evaluation and has ringworm on the buttocks, face, or elsewhere, especially if they are sexually active, the question of TMVII should arise, and the patient should be asked about possible genital lesions as well,” he said. “Any patient diagnosed with an STI [sexually transmitted infection], including MSM patients, should be evaluated appropriately for other STIs including TMVII.” 

Continued surveillance and monitoring are needed to track TMVII and to better understand emerging infections, Caplan told this news organization. Clinicians can find more information and a dermatophyte registry via the American Academy of Dermatology websites on emerging diseases in general and dermatophytes in particular.

“We also need better access to testing and more rapid confirmatory testing to detect emerging dermatophyte strains and monitor antifungal resistance patterns,” Caplan added. “At this time, we do not have evidence to suggest there is antifungal resistance in TMVII, which also distinguishes it from T indotineae.” 

 

Encourage Reporting and Identify New Infections

“Emerging infections can mimic noninfectious disease processes, which can make the diagnosis challenging,” Shirin A. Mazumder, MD, associate professor and infectious disease specialist at the University of Tennessee Health Science Center, Memphis, said in an interview.

“Monitoring emerging infections can be difficult if the cases are not reported and if the disease is not widespread,” Mazumder noted. Educating clinicians with case reports and encouraging them to report unusual cases to public health helps to overcome this challenge.

In the clinical setting, skin lesions that fail to respond or worsen with the application of topical steroids could be a red flag for TMVII, Mazumder told this news organization. “Since the skin findings of TMVII can closely resemble noninfectious processes such as eczema or psoriasis, the use of topical corticosteroids may have already been tried before the diagnosis of TMVII is considered.” 

Also, location matters in making the diagnosis. TMVII lesions occur on the face, genitals, extremities, trunk, and buttocks. Obtaining a thorough sexual history is important because the fungus spreads from close contact through sexual exposure, Mazumder added.

The most effective treatment for TMVII infections remains to be determined, Mazumder said. “Treatment considerations such as combination treatment with oral and topical antifungal medications vs oral antifungal medication alone is something that needs further research along with the best treatment duration.”

“Determining the rate of transmissibility between contacts, when someone is considered to be the most infectious, how long someone is considered infectious once infected, and rates of reinfection are questions that may benefit from further study,” she added.

Although the current cases are reported in MSM, determining how TMVII affects other patient populations will be interesting as more cases are reported, said Mazumder. “Further understanding of how different degrees of immunosuppression affect TMVII disease course is another important consideration.” 

Finally, determining the rate of long-term sequelae from TMVII infection and the rate of bacterial co-infection will help better understand TMVII, she said.

The researchers had no financial conflicts to disclose. Mazumder had no financial conflicts to disclose.

A version of this article first appeared on Medscape.com.